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ABSTRACT	  
Almutairi,	   Mohammed.	   M.S.,	   Department	   of	   Pharmacology	   and	   Toxicology,	  
Wright	   State	   University,	   Boonshoft	   School	   of	   Medicine,	   2014.	   Role	   of	  
Bumetanide	  on	  Insulin	  Secretion	  
	  
Insulin	  secretion	  depends	  on	  the	  electrical	  properties	  of	  the	  ß-­‐cells	  in	  
pancreatic	   islets.	   The	   consensus	   mechanism	   of	   insulin	   secretion	   involves	  
glucose-­‐stimulated	  metabolic	   increase	   in	   the	   ATP/ADP	   ratio.	   This	   increase	  
closes	  ATP-­‐sensitive	  K+	  (KATP)	  channels	  resulting	  in	  ß-­‐cell	  plasma	  membrane	  
depolarization,	   which	   in	   turn	   activates	   voltage-­‐dependent	   Ca2+	   channels	  
further	   resulting	   in	   Ca2+	   influx	   and	   release	   of	   insulin	   stored	   in	   granules.	   In	  
addition	   to	   this	   well-­‐known	   consensus	   mechanism,	   insulin	   secretion	   also	  
depends	   on	   electrogenic	   efflux	   of	   Cl–	   ions.	   The	   Na+K-­‐2Cl–	   cotransporters	  
(NKCCs)	   maintain	   the	   intracellular	   concentration	   of	   Cl–	   ([Cl–]i)	   at	   values	  
higher	  than	  those	  predicted	  at	  thermodynamic	  equilibrium.	  This	  distribution	  
of	   Cl–	   makes	   possible	   the	   electrogenic	   exit	   of	   the	   anion	   from	   ß-­‐cells	   upon	  
opening	   of	   volume-­‐regulated	   anion	   channels	   (VRAC).	   Therefore,	   the	  
prevailing	  notion	  states	  that	  disruption	  of	  the	  ß-­‐cell	  Cl–	  gradient	  by	  inhibition	  
of	   NKCCs	   with	   loop	   diuretics	   such	   as	   furosemide	   or	   bumetanide	   (BTD)	  
impairs	  insulin	  secretion.	  Our	  results	  challenge	  that	  long-­‐standing	  concept	  by	  
demonstrating	   that	   long-­‐term	   BTD	   does	   not	   impair	   insulin	   secretion	   in	  
mouse	  ß-­‐cells	   in	  vitro	   and	   that	   this	  effect	   is	   related	   to	  changes	   in	   the	  NKCC	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INTRODUCTION	  
Glucose	  Metabolism	  
In	   the	   post-­‐absorptive	   (fasting)	   state,	   normal	   plasma	   glucose	   levels	  
i.e.,	  euglycemia	  is	  kept	  within	  the	  range	  of	  60-­‐115	  mg/dl	  (3.6	  mM	  to	  6.3	  mM)
mainly	   as	   a	   result	   of	   the	   homeostatic	   balance	   between	   glucose	   use	   or	  
disposal	  and	   its	  endogenous	  production.	  Under	   fasting	  conditions,	  ~75%	  of	  
total	   glucose	   is	   normally	   used	   by	   tissues	   such	   as	   the	   brain	   (50%)	   liver,	  
gastrointestinal	   tissues	  and	  kidneys	  (25%).	  The	  muscle	  and	  adipose	   tissues	  
utilize	   the	   25%	   left	   of	   glucose	   in	   an	   insulin-­‐dependent	   manner.	   Overall,	  
whilst	  glucose	  under	  basal	  fasting	  conditions	  is	  used	  by	  tissues	  at	  a	  rate	  of	  ~2	  
mg/kg/min,	  endogenous	  glucose	  production	  matches	  that	  rate,	  thus	  keeping	  
basal	  blood	  glucose	  levels	  relatively	  constant	  (DeFronzo	  2004).	  	  
Two	  main	  mechanisms	  are	  involved	  in	  glucose	  production	  in	  the	  post-­‐
absorptive	  state.	  These	  are:	  glycogenolysis	  (glucose	  production	  from	  stored	  
glycogen)	   and	   gluconeogenesis	   (de	   novo	   glucose	   production	   from	   non-­‐
glucose	  precursors)	  (Bisschop,	  et	  al.	  2000).	  Most	  of	  total	  endogenous	  glucose	  
comes	   from	  the	   liver	  whereas	  a	  relatively	  small	  proportion	  comes	  from	  the	  
kidneys	   and	   intestines	   (Figure	   1)	   (Gerich	   2010).	   The	   liver,	   kidney	   and	  
intestines	   are	   the	   only	   organs	   expressing	   enough	   glucose-­‐6-­‐phosphatase	  
activity;	  the	  key	  enzyme	  involved	  in	  the	  delivery	  of	  endogenously	  produced	  
glucose	   into	   the	   circulation	   (Mithieux,	   et	   al.	   2004).	   Although	   in	   the	   liver	  
glycogen	  stores	  and	  de	  novo	  biosynthesis	  contribute	  equally	  to	  the	  basal	  rate	  
of	  glucose	  production,	  the	  kidneys	  provide	  glucose	  via	  gluconeogenesis	  only	  
(Stumvoll,	   et	   al.	   1997).	   In	   fact,	   the	   kidney	   may	   represent	   ~40%	   of	   total	  
gluconeogenesis	   in	   the	   post-­‐absorptive	   state	   (Meyer,	   et	   al.	   2002b).	   In	  

















































Figure 1. Glucose metabolism: Biosynthesis and utilization. A. Proportional view of total 
endogenous glucose production through glycogenolysis (glycogen breakdown) or gluconeogenesis 
from de novo biosynthesis or from gluconeogenic substrates such as glycerol, pyruvate, lactate or amino 
acids. B. Post-absorptive i.e., fasting (<12-16 hs) sources of endogenous glucose. C. Post-prandial (~2 
hs after a meal) sources of endogenous glucose. D. Proportional view of total glucose uptake from 
tissues and its use. E-F. Proportional approximate tissue distribution of glucose uptake during fasting (E) 
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addition,	   because	   hepatic	   glycogenolysis	   lasts	   until	   glycogen	   stores	   are	  
depleted,	   a	   task	   that	  may	   require	   up	   to	   48	   hours	   (Gerich	   2010),	   after	   that	  
period	   of	   time	   virtually	   all	   hepatic	   glucose	   delivery	   comes	   from	   de	   novo	  
synthesis	  of	  glucose	  from	  a	  variety	  of	  substrates	  (Consoli,	  et	  al.	  1987;	  Landau,	  
et	   al.	   1996).	   Therefore,	   the	   balance	   between	   glycogenolysis	   and	  
gluconeogenesis	   depends	   on	   the	   duration	   of	   fasting	   and	   usually,	   after	   a	  
prolonged	   fasting	   (overnight	   or	   longer),	   all	   of	   endogenous	   glucose	  may	   be	  
provided	   by	   hepatic,	   intestinal	   and	   renal	   gluconeogenesis	   (Gerich	   2010).	  
Although	  different	  substrate	  sources	   including	   lactate,	  glycerol,	   alanine	  and	  
other	  amino	  acids	  can	  be	  used	  for	  gluconeogenesis,	  the	  kidney	  and	  liver	  may	  
share	  some	  but	  not	  all	  gluconeogenic	  precursors.	  For	  instance,	  lactate	  is	  the	  
main	   source	   of	   hepatic	   and	   renal	   glucose.	   In	   fact,	   the	   kidney	   prefers	  
glutamine	   (Meyer	   et	   al.	   2002b)	  whilst	   almost	   all	   of	   alanine	   is	   converted	   to	  
glucose	  in	  the	  liver	  (Stumvoll,	  et	  al.	  1998).	  
While	   gluconeogenesis	   is	   activated,	   in	   parallel,	   tissues	   completely	  
oxidize	   endogenously	   produced	   glucose	   to	   provide	   energy	   or	   to	   produce	  
lactate	  by	  anaerobic	  glycolysis,	  which	  in	  turn	  may	  be	  used	  mostly	  by	  the	  liver	  
or	  in	  less	  extent	  by	  the	  kidneys	  to	  produce	  glucose	  via	  gluconeogenesis.	  The	  
hepatic	   glucose	   produced	   from	   lactate	   returns	   to	   the	   muscles	   to	   produce	  
lactate	   again	   i.e.,	   the	  Cori's	   cycle	   (Lehninger,	   et	   al.	   2013).	   It	   is	   important	   to	  
mention	   here	   that	   the	   kidneys	   and	   intestines	   by	   themselves	   are	   able	   to	  
sustain	   euglycemia	   in	   the	   absence	   of	   hepatic	   gluconeogenesis	   (Mutel,	   et	   al.	  
2011).	  	  	  
In	  the	  post-­‐prandial	  state	  or	  after	  a	  meal,	  plasma	  levels	  of	  glucose	  are	  
heavily	   dependent	   on	   insulin	   and	   glucagon	   release	   from	   the	   endocrine	  
pancreas	   (see	   bellow)	   as	   well	   as	   other	   hormones.	   It	   is	   the	   combination	   of	  
transient	   high	   levels	   of	   plasma	   glucose	   (hyperglycemia)	   and	   glucose-­‐
stimulated	  plasma	   insulin	   (hyperinsulinemia)	   the	   responsible	   for	   increased	  
glucose	   uptake	   by	   tissues,	   principally	   muscles,	   liver,	   kidneys	   and	   brain	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(85%),	  and	  in	  a	  less	  extent	  by	  the	  gut	  and	  fat	  tissues	  (~5%).	  Glucose	  uptake	  
facilitated	   or	   promoted	   by	   increased	   insulin	   in	   some	   but	   not	   all	   tissues	   is	  
accompanied	   by	   inhibited	   glycogenolysis	   and	   a	   virtual	   cease	   of	  
gluconeogenesis	   in	   the	   liver	   (Meyer,	   et	   al.	   2002a).	   In	   the	   kidneys,	   insulin	  
initially	   inhibits	   glucose	   release	   (Cersosimo,	   et	   al.	   1994).	   However,	   renal	  
gluconeogenesis	   is	   not	   blocked.	   In	   fact,	   it	   doubles	   after	   a	   meal	   as	   a	  
consequence	   of	   a	   gradual	   increase	   in	   glucagon	   release	   (Figure	   1)	   (Gerich	  
2010).	  	  
The	  endocrine	  pancreas	  
The	   endocrine	   unit	   of	   the	   pancreas,	   i.e.,	   the	   islet	   of	   Langerhans	  
consists	  of	  several	  endocrine	  cells,	  some	  of	  them	  with	  the	  remarkable	  ability	  
to	   respond	   to	   changes	   in	  blood	  glucose	   levels	  with	  appropriate	  amounts	  of	  
insulin,	  glucagon	  or	  other	  hormones.	  The	  ß-­‐cells,	  which	  account	  for	  most	  of	  
all	   endocrine	   cells	   of	   the	   islet	   (Chen,	   et	   al.	   2012),	   are	   the	   ones	   that	   sense	  
hyperglycemia,	   releasing	   insulin,	  which	   restores	   euglycemia.	   As	  mentioned	  
earlier,	   insulin	   increases	   glucose	   uptake	   from	   many	   peripheral	   tissues,	  
promotes	  excess	  glucose	  storage	  as	  glycogen	  and	  prevents	  glycogenolysis	  i.e.,	  
glycogen	  breakdown	  in	  the	  liver	  (MacDonald,	  et	  al.	  2005).	  However,	  insulin	  is	  
not	  the	  only	  hormone	  produced	  by	  the	  islets.	  In	  fact,	  the	  islet	  of	  Langerhans	  
regulates	  glucose	  and	  carbohydrate	  homeostasis	  by	  producing	  and	  releasing	  
several	  hormones	   from	  unique	  sets	  of	  cells.	  So	   far	   the	  mammalian	   islet	  has	  
five	  different	  cell	  types	  with	  the	  ability	  to	  produce	  different	  hormones.	  These	  
cells	   are:	  α-­‐cells	   (glucagon),	  δ-­‐cells	   (somatostatin),	   PP-­‐cells	   (pancreatic	  
polypeptide),	   enterochromaffin-­‐cells	   (serotonin),	   G-­‐cells	   (gastrin)	   and	   a	  
recently	   discovered	   cell	   type	  which	   produces	   a	   hormone	   able	   to	   stimulate	  
growth	  hormone	  release	  and	  originally	  named	  GH-­‐relin	  (ghrelin)	  (Wierup,	  et	  
al.	  2014).	  Of	  all	  the	  islet	  hormones,	  insulin	  is	  the	  only	  one	  with	  hypoglycemic	  
function	   and	   therefore,	   impairment	   of	   the	   ability	   of	   ß-­‐cells	   to	   respond	  
adequately	   to	   hyperglycemia	   represents	   a	   key	   component	   in	   the	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pathogenesis	  of	  diabetes	  mellitus	  (DeFronzo	  2004).	  	  	  
Most	  common	  types	  of	  Diabetes	  Mellitus	  
Diabetes	  mellitus	  (DM)	  can	  be	  defined	  as	  a	  poly-­‐endocrine	  and	  multi-­‐
metabolic	  syndrome,	  which	  results	  from	  chronic,	  uncontrolled	  high	  levels	  of	  
blood	   glucose	   due	   to	   impaired	   insulin	   secretion,	   action	   or	   both	   (DeFronzo	  
2004).	   DM	   is	   multi-­‐metabolic,	   because	   all	   aspects	   of	   metabolism	   are	  
impacted	   by	   the	   reduced	   or	   absent	   capacity	   of	   tissues	   to	   properly	   utilize	  
glucose	  as	  the	  main	  source	  of	  energy	  as	  a	  consequence	  of	  insulin	  deficiency.	  
Poly-­‐endocrine,	   because	   the	   relative	   or	   absolute	   deficiency	   of	   insulin	  
unbalances	   the	   ability	   of	   other	   hormones	   to	   properly	   exert	   their	   function	  
aggravating	  the	  diabetic	  picture	  (DeFronzo	  2004).	  Therefore,	  it	  is	  important	  
to	  keep	  in	  mind	  that	  diabetes	  mellitus	  is	  not	  a	  single	  entity	  but	  comprises	  a	  
group	  of	  metabolic	  diseases	  with	   the	  most	  notable	  characteristic	  of	  chronic	  
hyperglycemia	   as	   a	   result	   of	   impaired	   insulin	   secretion,	   insulin	   action,	   or	  
both.	  It	  is	  the	  chronically	  elevated	  glycemia	  the	  one	  associated	  with	  the	  long-­‐
term	   neural,	   micro-­‐	   or	   macro-­‐vascular	   and	   many	   other	   co-­‐morbid	  
complications	   observed	   in	   patients	   with	   diabetes,	   which	   in	   turn	   make	   the	  
diabetic	   picture	   very	   difficult	   to	   control.	   This	   is	   highlighted	   in	   some	   of	   the	  
most	  recent	  reviews	  (Ackermann	  and	  Hart	  2013;	  Aslam,	  et	  al.	  2014;	  Bordier,	  
et	   al.	   2014;	   Charnogursky,	   et	   al.	   2014;	   Cunha-­‐Vaz,	   et	   al.	   2014;	   Mora-­‐
Fernandez,	  et	  al.	  2014;	  Paneni,	  et	  al.	  2014;	  Prieto,	  et	  al.	  2014;	  Siddiqui	  2014;	  
Szuszkiewicz-­‐Garcia	  and	  Davidson	  2014;	  Wang,	  et	  al.	  2014).	  
Of	   the	   many	   forms	   of	   DM	   classified	   by	   the	   American	   Diabetes	  
Association	   (Diabetes	   Care	   27:Suppl1,	   S5-­‐S10,	   2004),	   the	   vast	   majority	   of	  
cases	  fall	  within	  two	  main	  groups	  named	  Type	  1	  and	  Type	  2	  DM	  (T1DM	  and	  
T2DM,	   respectively).	   T1DM	   is	   characterized	   by	   virtually	   absent	   insulin	  
secretion	  due	   to	   autoimmune	  destruction	  of	   insulin-­‐secreting	  ß-­‐cells	   of	   the	  
pancreas.	  The	  diabetic	  syndrome	  in	  T1DM	  appears	  suddenly	  and	  early	  in	  life	  
and	  its	  treatment	  depends	  exclusively	  on	  daily	  external	   insulin	  injections	  in	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order	  to	  normalize	  blood	  glucose	  and	  to	  allow	  tissues	  to	  use	  it.	  This	  type	  of	  
diabetes	  is	  not	  commonly	  associated	  with	  obesity	  and	  usually	  is	  diagnosed	  in	  
childhood.	   T2DM,	   is	   a	   significantly	   more	   prevalent	   entity	   considered	   non-­‐
insulin	   dependent	   and	   characterized	   by	   relative	   deficiency	   of	   insulin	  
manifested	   either	   by	   impaired	   insulin	   secretion,	   tissue	   resistance	   to	   the	  
action	   of	   insulin	   or	   a	   variable	   combination	   of	   both.	   The	   impaired	   insulin	  
secretory	   response	   characteristic	   of	   T2DM	   correlates	   with	   variable	  
hyperglycemia	  often	  times	  sufficient	  to	  impact	  the	  normal	  function	  of	  various	  
tissues,	   but	   initially	   without	   clinical	   symptoms.	   Typically,	   impaired	   insulin	  
secretion	   is	   first	   reflected	   in	   abnormal	   carbohydrate	   metabolism,	   usually	  
diagnosed	  when	  plasma	  glucose	  levels	  are	  higher	  than	  7.8	  mM	  either	  under	  
fasting	   conditions	   or	   2	   hours	   after	   a	   standardized	   oral	   glucose	   load	   i.e.,	  
glucose	   tolerance	   test.	   The	   detailed	   full	   diagnostic	   criterion	   adopted	  
worldwide	   can	   be	   obtained	   from	   the	   World	   Health	   Organization	   Diabetes	  
Program	  	  (www.who.int/diabetes/publications/en/).	  
T2DM	   is	   a	   common	   syndrome	   with	   almost	   endemic	   proportions.	  
According	   to	   the	   International	   Diabetes	   Federation	   (www.idf.org),	   T2DM	  
impacts	   the	   quality	   of	   life	   of	  ~380	  million	   individuals	   in	   the	  world	   and	   its	  
prevalence	  is	  expected	  to	  almost	  double	  by	  the	  year	  2035.	  There	  are	  several	  
factors	  involved	  in	  pathogenesis	  of	  T2DM	  such	  as	  genetic	  and	  environmental	  
factors.	   In	   fact,	   the	   multifactorial	   nature	   of	   T2DM	   has	   made	   virtually	  
impossible	   to	   elucidate	   the	   pathogenic	   mechanisms	   of	   the	   disease.	   As	  
mentioned	  above,	   the	  main	   characteristic	   of	  patients	  with	  T2DM	   is	   chronic	  
hyperglycemia	   whereas	   the	   myriad	   of	   complications	   brought	   about	  
hyperglycemia	  is	  highly	  dependent	  on	  the	  population	  studied,	  environmental	  
factors,	  lifestyle,	  obesity,	  stress,	  aging,	  and	  other	  factors.	  (Leahy	  2005).	  	  
The	  Biphasic	  Nature	  of	  Insulin	  Secretion	  
Glucose	  has	  a	  direct,	  concentration-­‐	  and	  time-­‐dependent	  impact	  on	  ß-­‐
cells	   promoting	   insulin	   release	   in	   a	   characteristically	   biphasic	   time	   course	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(Grodsky	  1972).	  The	  biphasic	  nature	  of	  insulin	  secretion	  is	  chiefly	  observed	  
in	   rat	   and	   human	   islets	   but	   is	   usually	   weak	   in	  mouse	   islets	   and,	   with	   few	  
exceptions,	  mostly	   absent	   in	   several	   rodent	   ß-­‐cell	   lines	   (Nunemaker,	   et	   al.	  
2006).	  The	  first	  phase	  of	  insulin	  secretion	  occurs	  rapidly	  after	  insulinotropic	  
blood	   glucose	   levels,	   usually	   higher	   than	   5.5-­‐6.0	   mM.	   The	   raise	   in	   insulin	  
secretion	  stimulated	  by	  insulinotropic	  glucose	  is	  sharp	  and	  accounted	  for	  the	  
insulin	  contained	  in	  primed	  secretory	  granules	  of	   the	  ß-­‐cell	  (Henquin,	  et	  al.	  
2002).	   This	   first	   phase	   of	   insulin	   secretion	   is	   the	   responsible	   for	   adequate	  
postprandial	   glucose	   uptake	   by	   tissues	   and	   therefore,	   its	   impairment	   is	  
clinically	   manifested	   as	   glucose	   intolerance.	   In	   other	   words,	   insufficient	  
insulin	  secreted	  in	  response	  to	  glucose	  is	  not	  enough	  to	  clear	  plasma	  glucose	  
at	  a	  normal	  rate.	  
The	  first	  phase	  of	   insulin	  secretion	  does	  not	   last	   long.	   It	   is	  overcome	  
by	   the	  second	  phase	  characterized	  by	  a	  slow	  but	  steady	   increase	   in	  plasma	  
insulin	  levels	  that	  last	  a	  couple	  of	  hours.	  The	  insulin	  secreted	  in	  this	  second	  
phase	  represents	  de	  novo	  biosynthesis	  of	  the	  hormone	  by	  ß-­‐cells	  as	  well	  as	  
insulin	  stored	  in	  granules	  not	  released	  during	  the	  first	  phase	  (Henquin	  et	  al.	  
2002).	  It	  is	  this	  phase	  the	  one	  responsible	  of	  restoring	  euglycemia.	  In	  T2DM	  
patients	   this	   second	   phase	   is	   not	   usually	   as	   compromised	   as	   the	   first	   one,	  
explaining	  the	  fact	  that	  these	  patients	  may	  reach	  values	  close	  to	  euglycemia,	  
although	  after	  longer	  periods	  of	  time	  relative	  to	  normal	  individuals	  (Figure	  
2)	  (DeFronzo	  2004).	  	  
The	   First	   Phase	   of	   Insulin	   Secretion:	   The	   ATP-­‐dependent	   (KATP)-­‐
channel-­‐dependent	  mechanism	  
The	   best-­‐known	   mechanism	   involved	   in	   the	   first	   phase	   of	   insulin	  
secretion	   is	   the	   one	   dependent	   on	   ATP-­‐sensitive	   K+	   (KATP)	   channels	  
(Komatsu,	   et	   al.	   2013).	  This	  mechanism	  has	   its	   foundations	  on	   the	   seminal	  
observations	   of	   Dean	   &	   Matthews	   in	   1968,	   the	   characteristic,	   albeit	   not	  
unique	   electrophysiology	   of	   ß-­‐cells	   and	   the	   cloning	   followed	   by	  molecular,	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Figure 2. Impairment or absence of the first phase of insulin secretion causes 
Diabetes Mellitus. In normal individuals, insulin is secreted in response to glucose 
in a typical biphasic manner where the first phase is prominently high and fast. In 
individuals with T2DM, however, the first phase of insulin secretion is lost. However, 
the second phase is usually seen. Contrary to the normal populatiopn or T2DM, 
patients with T1DM do not secrete insulin in response to glucose due to destruction 
of ß-cells. Plots made from data published in Pfeifer et al. Am. J. Med 1981 
70:579–588.
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functional	   characterization	   and	   reconstitution	   of	   the	   KATP	   channels	   in	   the	  
nineties	   (Aguilar-­‐Bryan,	   et	   al.	   1995;	   Ashcroft,	   et	   al.	   1984;	   Cook	   and	   Hales	  
1984;	  Dean	  and	  Matthews	  1968;	  Inagaki,	  et	  al.	  1995;	  Nichols,	  et	  al.	  1996).	  
The	   KATP-­‐dependent	   mechanism	   of	   insulin	   secretion	   can	   be	  
summarized	  as	  follows:	  glucose	  transporters	  present	  in	  the	  surface	  of	  ß-­‐cells	  
facilitate	  glucose	  entry	  into	  the	  cell	  where	  it	   is	   immediately	  phosphorylated	  
by	  the	  action	  of	  a	  glucokinase	  and	  further	  metabolized	  via	  glycolysis.	  Glucose	  
metabolism	   increases	   the	   ATP/ADP	   ratio	   resulting	   in	   the	   closure	   of	   KATP	  
channels	   and	   membrane	   depolarization	   due	   to	   decreased	   K+	   conductance.	  
Plasma	  membrane	  depolarization	  activates	  voltage-­‐dependent	  Ca+2	  channels	  
promoting	  massive	   Ca+2	   influx,	   the	   ultimate	   trigger	   of	   insulin	   release	   from	  
storage	  granules	  (Komatsu	  et	  al.	  2013).	  At	  non-­‐insulinotropic	  glucose	  levels	  
(<5.5-­‐6.0	  mM)	  the	  probability	  of	  KATP	  channels	  to	  be	  in	  the	  open	  state	  is	  high.	  
This	  permits	   the	  normal	  "leakage"	  of	  K+	   ions	  out	  of	   the	  cell,	  which	  with	  the	  
action	   of	   the	   Na/K-­‐ATPase	   help	   maintain	   a	   resting	   hyperpolarized	  
membrane	  potential	  of	  −70	  mV	  (Ashcroft	  et	  al.	  1984;	  Cook	  and	  Hales	  1984;	  
Dean	   and	  Matthews	   1968,	   1970;	  MacDonald	   et	   al.	   2005).	   This	  mechanism,	  
considered	   the	   consensus	   model	   of	   glucose-­‐induced	   insulin	   secretion	   is	  
schematized	  in	  Figure	  3.	  	  
Notably,	   the	   consensus	   mechanism	   of	   insulin	   secretion	   has	   been	  
dogmatically	   considered	   the	   exclusive	   and	   only	   one,	   until	   a	   series	   of	  
experiments	  in	  the	  nineties	  demonstrated	  that	  KATP	  channels	  are	  dispensable	  
for	  insulin	  secretion	  [reviewed	  in	  (Best,	  et	  al.	  2010)].	  Further,	  the	  cloning	  and	  
reconstitution	   of	   ß-­‐cell	   KATP	   channels	   in	   1995	   by	   Aguilar-­‐Bryan,	   Seino	   and	  
collaborators	   (Aguilar-­‐Bryan	   et	   al.	   1995;	   Inagaki	   et	   al.	   1995;	   Nichols	   et	   al.	  
1996)	  opened	  up	  several	  new	  avenues	  to	  study	  the	  consensus	  mechanism	  of	  
insulin	  secretion.	  The	  elucidation	  of	  the	  minimum	  requirements	  for	  the	  KATP	  
channel	   to	   form	   and	   transport	   K+	   i.e.,	   4	   subunits	   of	   the	   sulphonylurea	  
receptor	   (SUR1)	   and	   4	   subunits	   of	   the	   inwardly	   rectifier	   K+	   channel	   6.2	  



















































Figure 3. Simplified version of the consensus model of insulin secretion: the 
KATP-dependent pathway. A (left). Under basal conditions, the KATP channels of the 
ß-cells are open allowing the exit of K+ ions and, with the functional activity of the 
Na/K-ATPase (not represented in the diagram) maintain the cell hyoperpolarized at <70 
mV. Under this conditions, glucose metabolism within the ß-cells is minimum and 
therefore the ATP/ADP ratio is low. A (right). Upon hyperglycemia, glucose enters the 
ß-cell by facilitated diffusion via glucose transporters and is metabolized via glucolysis. 
The resulting increase in the ATP/ADP ratio inhibits KATP channels depolarizing the 
plasma membrane to values enough to activate voltage-dependent Ca2+-channels 
(VDCC). This allow the entrance of Ca 2+ and the increase in its intracellular 
concetration; the trigger of insulin secretion. B. Represented are the changes in 
membrane potential (red), intracellular concentration of Ca2+ (blue) and insulin 
secretion in fold changes (green) under basal low or high glucose conditions.
A
B
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(Kir6.2)	   permitted	   not	   only	   to	   determine	   the	   mechanisms	   of	   action	   of	  
sulfonylureas,	   the	   most	   commonly	   prescribed	   drugs	   to	   manage	  
hyperglycemia,	   but	   also	   the	   creation	   of	   mice	   lacking	   either	   of	   the	   two	  
subunits	   of	   the	   KATP	   channel	   i.e.,	   Kir-­‐KO	   (Miki,	   et	   al.	   1998)	   and	   SUR-­‐KO	  
(Seghers,	   et	   al.	   2000).	   Surprisingly,	   these	   mice	   presented	   normal	   glucose	  
homeostasis	  (Dufer,	  et	  al.	  2004;	  Miki	  et	  al.	  1998;	  Rosario,	  et	  al.	  2008;	  Seghers	  
et	  al.	  2000;	  Szollosi,	  et	  al.	  2007).	  These	  results	  confirmed	  earlier	  and	  almost	  
forgotten	   experiments	   demonstrating	   that	   pancreatic	   ß-­‐cells	   depolarize,	  
increase	   [Ca2+]i	   and	   release	   insulin	   in	   response	   to	   physiological	   glucose	  
concentrations	   in	   the	   absence	   of	   functional	   KATP	   activity	   (Best	   and	   Brown	  
2009;	  Best,	  et	  al.	  1992;	  Gembal,	  et	  al.	  1993;	  Gembal,	  et	  al.	  1992;	  Sato,	  et	  al.	  
1992).	   Altogether,	   these	   results	  were	   considered	   proof	   for	   the	   presence	   of	  
additional	   KATP	   channel	   independent	   mechanisms	   involved	   in	   insulin	  
secretion.	  One	  of	  these	  mechanisms	  is	  directly	  related	  to	  the	  ability	  of	  ß-­‐cells	  
to	  depolarize	  via	  volume-­‐regulated	  anion	  channels	  (VRAC).	  	  
The	   first	   phase	   of	   insulin	   secretion:	   Mechanisms	   independent	   of	   the	  
KATP	  channel	  
In	   addition	   to	   ATP,	   glucose	  metabolism	   produces	   osmotically	   active	  
metabolites	  with	  the	  natural	  ability	  to	  promote	  water	  influx	  (Beauwens,	  et	  al.	  
2006;	   Best	   1999,	   2002;	   Best	   and	   Brown	   2009).	   Therefore,	   glucose	  
metabolism	  swells	  ß-­‐cells,	  which	  in	  turn	  results	  in	  the	  activation	  of	  VRAC	  and	  
the	   consequent	   exit	   of	   anionic	  osmolytes	   thus	  bringing	   cell	   volume	  back	   to	  
normal	  (Hoffmann,	  et	  al.	  2009).	  The	  physiology	  of	  VRAC	  has	  been	  extensively	  
studied	  in	  ß-­‐cells	  after	  the	  pioneering	  work	  of	  Len	  Best	  (Best	  1999),	  Les	  Satin	  
(Kinard,	   et	   al.	   2001),	   collaborators	   and	   others	   [extensively	   reviewed	   in	   (Di	  
Fulvio,	   et	   al.	   2014)].	   Notably,	   the	   molecular	   identity	   of	   VRAC	   remained	  
unknown	   until	   early	   2014	   when	   two	   papers	   published	   almost	  
simultaneously	   identified	   the	   product	   of	   the	   leucine-­‐rich	   repeat-­‐containing	  
protein	  8A	  (LRRC8A)	  gene	  as	  an	  essential	  component	  of	  VRAC,	  a	  multimeric	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complex	  composed	  of	  several	  subunits	  of	  homologous	  LRRC8	  genes	  with	  the	  
ability	  to	  reconstitute	   in	  vitro	  a	  VRAC	  with	  the	  typical	   functional	  properties	  
which	   have	   been	   known	   for	   many	   years,	   in	   particular	   hypotonicity	   (cell	  
swelling)-­‐stimulated	  anion	  fluxes	  and	  high	  permeability	  to	  Cl–	  ions	  (Qiu,	  et	  al.	  
2014;	  Voss,	  et	  al.	  2014).	  
Indeed,	   VRAC	   tansports	   several	   anions	   but	   prefers	   Cl–	   (Best	   2002;	  
Best	  and	  Brown	  2009;	  Best,	  et	  al.	  1997;	  Best	  and	  Yates	  2010),	  which	  together	  
with	   bicarbonate	   constitutes	   the	   most	   abundant	   anion	   in	   living	   cells.	   This	  
implies	   that	   VRAC	   transports	   Cl–	   inward	   or	   outward	   according	   to	   the	  
electrochemical	  gradient	  of	  the	  anion	  in	  a	  given	  cell	  (see	  Figure	  4).	  Now	  we	  
know	  that	  in	  ß-­‐cells	  the	  net	  flux	  of	  Cl–	  is	  outward	  and	  therefore,	  electrogenic	  
and	   depolarizing.	   To	   explain	   the	   electrogenic,	   depolarizing	   and	   VRAC-­‐
mediated	  Cl–	  efflux	  induced	  by	  glucose	  in	  ß-­‐cells,	  we	  have	  to	  understand	  how	  
Cl–	   ions	   are	   transported	   into	   the	   cell	   in	   order	   to	   attain	   an	   intracellular	  
concentration	  ([Cl–]i)	  high	  enough	  to	  support	   its	  depolarizing	  efflux	  from	  ß-­‐
cells	   holding	   a	   membrane	   potential	   (Em)	   of	   −70	  mV	   (Dean	   and	  Matthews	  
1968).	  Indeed,	  at	  such	  Em	  and	  a	  physiological	  extracellular	  concentration	  of	  
Cl–	  around	  130	  mM,	  the	  Nernst	  equation	  predicts	  [Cl–]i	  of	  ~10	  mM	  [reviewed	  
in	   (Di	   Fulvio	   et	   al.	   2014)].	   Therefore,	   if	   ß-­‐cells	   had	   such	   [Cl–]i,	   the	   net	  
movement	  of	  Cl–	   ions	   i.e.,	   the	  algebraic	  sum	  of	   ions	  going	   in	  or	  going	  out	  of	  
the	   ß-­‐cell	  would	   be	   zero	   and	   therefore,	   no	   electrogenic	   Cl–	   fluxes	   could	   be	  
induced	   by	   glucose.	   However,	   ß-­‐cells	  maintain	   [Cl–]i	   above	   thermodynamic	  
equilibrium,	  i.e.,	  higher	  than	  the	  [Cl–]i	  predicted	  by	  the	  Nernst	  equation.	  
Indeed,	   in	  1978	  Sehlin	   first	   suggested	   that	   36Cl–	   accumulates	   against	  
its	   electrochemical	   gradient	   in	   isolated	   rat	   ß-­‐cells	   (Sehlin	   1978).	   Twenty	  
years	   later,	  Kozak	  &	  Logothetis	  demonstrated	  for	   the	   first	   time	  that	  [Cl–]i	   is	  
maintained	  above	  thermodynamic	  equilibrium	  in	  rodent	  ß-­‐cells	  as	  calculated	  
from	   its	   reversal	  potential	   (Kozak	  and	  Logothetis	  1997;	  Kozak,	   et	  al.	  1998)	  
and	   Eberhardson	   and	   collaborators	   directly	   measured	   [Cl–]i	   by	   using	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microfluorometric	   methods	   and	   demonstrated	   its	   levels	   to	   be	   above	  
equilibrium	  (Eberhardson,	  et	  al.	  2000).	  Now	  we	  known	  that	   [Cl–]i	   in	  rodent	  
ß-­‐cells	   is	   ~40	   mM	   i.e.,	   3-­‐4	   times	   the	   one	   predicted	   by	   thermodynamic	  
equilibrium.	  Therefore,	   this	   [Cl–]i	   does	   explain	   the	   electrogenic	   efflux	  of	   Cl–	  
originally	  demonstrated	   in	  response	  to	   insulinotropic	  glucose	  (Sehlin	  1978;	  
Sehlin	  and	  Meissner	  1988).	  	  
If	   [Cl–]i	   in	   ß-­‐cells	   is	   kept	   above	   thermodynamic	   equilibrium,	   it	  must	  
have	   mechanisms	   for	   its	   active	   accumulation.	   These	   mechanisms	   were	  
suspected	  in	  early	  experiments	  using	  ß-­‐cells	  of	  several	  species	  treated	  with	  
loop-­‐diuretics	   such	   as	   furosemide	   and	   bumetanide	   (Engstrom,	   et	   al.	   1991;	  
Sandstrom	   1988,	   1990;	   Sandstrom	   and	   Sehlin	   1987,	   1988a,	   b,	   c,	   d),	  
nowadays	   well-­‐known	   inhibitors	   of	   some	   Cl–	   transporters	   of	   the	   SLC12A	  
family	   of	   genes	   (Arroyo,	   et	   al.	   2013)	   (see	  bellow).	   Almost	   thirty	   years	   ago,	  
Sandstrom	  &	  Sehlin	  (1987)	  established	  for	  the	  first	  time	  that	  β-­‐cells	  contain	  
a	   bumetanide-­‐sensitive	  mechanism	   for	   36Cl–	   uptake	   (Sandstrom	   and	   Sehlin	  
1987).	  This	  seminal	   finding	  prompted	   the	   immediate	   test	  of	   the	  hypothesis	  
that	   loop-­‐diuretics	   inhibit	   insulin	   secretion.	   In	   a	   series	   of	   three	  papers,	   the	  
same	  authors	   reported	   that	  a	   single-­‐dose	  of	   furosemide	  provokes	   transient	  
hyperglycemia	   in	   animal	   models,	   that	   this	   diuretic	   may	   induce	   glucose	  
intolerance	  and	  that	   the	  negative	   impact	  of	   furosemide	  on	   insulin	  secretion	  
was	   directly	   related	   to	   inhibition	   of	   Cl–	   and	   Ca2+	   fluxes	   in	   the	   ß-­‐cell	  
(Sandstrom	   1990;	   Sandstrom	   and	   Sehlin	   1987,	   1988a,	   c).	   The	   parallel	  
discovery	  that	  ß-­‐cells	  express	  functional	  cotransport	  systems	  for	  Na+,	  K+	  and	  
Cl–	   ions	  and	  that	  this	  mechanism	  is	  sensitive	  to	  furosemide	  (Sandstrom	  and	  
Sehlin	  1987,	  1988a,	  b,	   c,	   d)	   gave	   immediate	   support	   to	   the	  hypothesis	   that	  
accumulation	   of	   Cl–	   in	   ß-­‐cells	   is	   active,	   sensitive	   to	   loop-­‐diuretics	   and	  
involved	   in	   insulin	   secretion.	   The	   definitive	   link	   between	   electrogenic	   Cl–	  
efflux	   and	   insulin	   secretion	   was	   established	   in	   an	   elegant	   series	   of	  
experiments	   in	   mouse	   pancreatic	   ß-­‐cells	   originally	   performed	   by	   Sehlin	   &	  
Meissner	  (Sehlin	  and	  Meissner	  1988).	  Even	  though	  the	  pharmacological	  and	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functional	   impact	   of	   bumetanide	   or	   furosemide	   on	   insulin	   secretion	  
appeared	   well	   established	   at	   that	   time,	   the	   molecular	   identity	   of	   the	  
diuretic's	  targets	  in	  ß-­‐cells	  had	  to	  wait	  another	  ten	  or	  so	  years.	  Nevertheless,	  
the	   simplified	  model	  presented	   in	  Figure	   4	   represents	   the	  concept	   that	  Cl–	  
exits	  ß-­‐cells	  depolarizing	  the	  plasma	  membrane	  	  
Cation-­‐coupled	  chloride	  co-­‐transporters:	  The	  SLC12A	  family	  
Of	   the	  numerous	   ion	   transporters	   involved	   in	   the	   regulation	  of	   [Cl–]i	  
several	  of	  them,	  nucleated	  in	  the	  solute	  carrier	  12	  group	  A	  (Slc12a	  in	  rodents	  
or	   SLC12A	   in	   non-­‐rodents	   or	   primates)	   family	   of	   cation-­‐coupled	   Cl–	  
cotransporters	   (CCCs)	   are	   considered	   the	   prototypical	   Cl–	   accumulators	  
(Slc12a1-­‐3	   isoforms	   and	   splice	   variants	  v1,	  v2,	  v3,	   and	   so	   on.)	   or	   extruders	  
(Slc12a4-­‐7	   isoforms	  and	  splice	  variants	  v1,	  v2,	  v3,	  and	  so	   forth)	  (see	  Figure	  
5).	   NKCC1	   (Slc12a2),	   NKCC2	   (Slc12a1)	   and	   the	   thiazide-­‐sensitive	   Na+Cl–	  
(NCC)	   cotransporters	   (Slc12a3)	   accumulate	   Cl–	   ions	   against	   its	  
electrochemical	   gradient	   increasing	   [Cl–]i	   to	   values	   typically	   above	  
thermodynamic	   equilibrium	   whereas	   K+Cl–	   cotransporters	   collectively	  
known	  as	  KCCs	  and	   individually	  named	  as	  KCC1	  (Slc12a4),	  KCC2	  (Slc12a5),	  
KCC3	   (Slc12a6)	   and	   KCC4	   (Slc12a7)	   are	   the	   ones	   with	   Cl–	   extrusion	  
capabilities	   and	   responsible	   for	   keeping	   [Cl–]i	   bellow	   thermodynamic	  
equilibrium.	   	   Since	   NKCCs	   are	   the	   targets	   of	   bumetanide,	   one	   of	   the	   most	  
commonly	  prescribed	  diuretics	  and	  ß-­‐cells	  keep	  a	  high	  [Cl–]i	  in	  a	  bumetanide-­‐
sensitive	  manner,	  the	  next	  sections	  concentrate	  on	  NKCC1	  and	  NKCC2.	  For	  a	  
detailed	  molecular	  analysis	  of	  KCCs,	   the	  reader	   is	  directed	   to	  other	  sources	  
(Arroyo	  et	  al.	  2013;	  Gagnon	  and	  Di	  Fulvio	  2013).	  
Na+K+2Cl–	  cotransporters	  
As	   mentioned	   above,	   two	   isoforms	   of	   NKCC	   produced	   by	   different	  
genes	   are	   known.	   These	   are:	   NKCC1	   and	   NKCC2,	   encoded	   by	   Slc12a2	   and	  
Slc12a1	   genes,	   respectively	   (Arroyo	   et	   al.	   2013;	   Markadieu	   and	   Delpire	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Figure 4. The high intracellular concentration of Cl< in 
ß-cells. Insulin-secreting ß-cells exhibit [Cl<]i above 
thermodynamic equilibrium due to the predominant activity of Cl< 
uptake mechanisms relative to those which extrude the anion. It 
is this high [Cl<]i the one that supports the exiting of the anion 
upon opening of any Cl< channel expressed in ß-cells, including 
volume-regulated anion channels (VRAC). Adapted from Di 
Fulvio & collaborators (2014).
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2014).	  NKCC1	  is	  expressed	  ubiquitously	  i.e.,	  abundantly	  in	  all	  cells	  studied	  so	  
far	  (Hoffmann	  et	  al.	  2009).	  However,	  there	  are	  some	  exceptions	  to	  this	  rule.	  
These	   include	   glucagon-­‐secreting	   rat	  α-­‐cells	   (Majid,	   et	   al.	   2001)	   or	   tubular	  
epithelial	   cells	   of	   the	   thick	   ascending	   loop	   of	   Henle	   (TALH)	   (Kaplan,	   et	   al.	  
1996).	  It	  is	  important	  to	  note	  that	  additional	  cell	  types	  might	  be	  found	  in	  the	  
future	  lacking	  NKCC1	  and	  therefore,	  the	  use	  of	  the	  epithet	  "ubiquitous"	  might	  
not	  be	  appropriate	  to	  designate	  NKCC1.	  At	  any	  rate,	  contrary	  to	  NKCC1,	  the	  
most	  abundant	  and	  almost	  exclusive	  source	  of	  NKCC2	  is	  the	  kidney.	  Indeed,	  
NKCC2	   is	  expressed	   in	   the	  mammalian	  kidney	   in	  such	  a	  high	   level	   that	   it	   is	  
considered	   "kidney-­‐specific"	   (Arroyo	   et	   al.	   2013;	   Markadieu	   and	   Delpire	  
2014).	  However,	  NKCC2	   has	   been	   found	   in	   several	   cell	   types	  where	   it	  was	  
searched,	  including	  insulin	  secreting	  rodent	  ß-­‐cells	  (Alshahrani,	  et	  al.	  2012).	  
Further,	   NKCC2	   has	   also	   been	   found	   in	   rat	   neurons	   of	  mesenteric	   ganglia,	  
secretomotor	  enteric	  neurons	  (Xue,	  et	  al.	  2009;	  Zhu,	  et	  al.	  2011),	  cells	  of	  the	  
gastric,	   colonic,	   intestinal,	   endolymphatic	   sac	   and	   olfactory	   epithelia	  
(Akiyama,	  et	  al.	  2010;	  Akiyama,	  et	  al.	  2007;	  Kakigi,	  et	  al.	  2009;	  Nickell,	  et	  al.	  
2007;	  Nishimura,	  et	  al.	  2009;	  Xue	  et	  al.	  2009;	  Xue,	  et	  al.	  2014;	  Zhu	  et	  al.	  2011)	  
and	   in	  starburst	  amacrine	  cells	  of	   the	  retina	  (Gavrikov,	  et	  al.	  2006).	   In	   fact,	  
large-­‐scale	  analysis	  of	   the	  human	  transcriptome	  demonstrated	   that	  Slc12a1	  
transcripts	   are	   widely	   distributed	   among	   tissues,	   although	   at	   much	   lower	  
levels	   when	   compared	   to	   kidney	   (Su,	   et	   al.	   2004).	   Notably,	   the	   main	  
functional	  difference	  between	  NKCC1	  and	  NKCC2	  is	   that	  the	  former	  has	  the	  
ability	   to	   transport	  water	  (Hamann,	  et	  al.	  2010)	  and	  therefore,	   it	   is	  directly	  
involved	  in	  cell	  volume	  regulation	  (Hoffmann	  et	  al.	  2009).	  NKCC2,	  however,	  
is	   a	   "dry"	   cotransporter	   (Zeuthen	   and	   Macaulay	   2012)	   mainly	   involved	   in	  
NaCl	  reabsorption	  by	   the	  TALH	  (Ares,	  et	  al.	  2011),	  where	  NKCC2	   is	  heavily	  
expressed	   and	   from	   where	   most	   if	   not	   all	   of	   our	   knowledge	   comes	   from	  
(Arroyo	   et	   al.	   2013;	  Markadieu	   and	  Delpire	   2014).	   Outside	   the	   kidney,	   the	  
functional	  impact	  of	  NKCC2	  is	  poorly	  understood.	  
At	  the	  molecular	  level,	  the	  mouse	  Slc12a2	  gene	  produces	  at	  least	  three	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Figure 5. Cladogram of Slc12a isoforms and splice variants. In silico 
phylogenetic neighbor-joining analysis using the genetic distance model of Jukes & 
Cantor (Evolution of Protein Molecules. New York: Academic Press. pp. 21–132, 
1969). Shown are the two main branches of the Slc12a family (Cl loaders and Cl 
extruders) as well as their respective sensitivities to diuretics. Graph generated by 
using Geneious R7 (Biomatters Ltd. NZ).
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alternative	  splice	  variants.	  These	  are	  annotated	  in	  the	  RefSeq	  database	  with	  
the	   following	   accession	   numbers:	   NM_009194	   (Slc12a2,	   NKCC1a),	  
XM_006525732	   (Slc12a2	  x1,	   NKCC1b)	   and	   XR_385981	   (Slc12a2	  x2).	   Except	  
for	   the	   latter,	   which	   was	   recently	   predicted	   by	   automated	   computational	  
analysis,	  mouse	  NKCC1a	  and	  NKCC1b	  mRNAs	  differ	  among	  themselves	  by	  the	  
inclusion	   of	   exon	   21.	   Indeed,	   NKCC1b	   lacks	   the	   16	   C-­‐terminal	   residues	  
encoded	  by	  that	  exon	  (Randall,	  et	  al.	  1997)	  (Figure	  6A).	  Both	  transcripts	  are	  
predicted	   to	   encode	   proteins	   of	   ~130	   kDa	   in	   its	   core/high-­‐mannose	   N-­‐
glycosylated	   form	   and	   of	   ~170	   kDa	   when	   hybrid/complex	   N-­‐glycosylated	  
(Singh,	   et	   al.	   2014).	   Hydropathy	   analysis	   of	   NKCC1	   sequences	   predicts	  
proteins	  with	  12-­‐transmembrane	  domains	  and	  two	  large	  intracellular	  N-­‐	  and	  
C-­‐termini	  (Di	  Fulvio	  and	  Alvarez-­‐Leefmans	  2009).	  Both	  NKCC1a	  and	  NKCC1b	  
exhibit	   similar	   functional	   properties	   but	   differ	   in	   their	   expression	   pattern	  
(Vibat,	   et	   al.	   2001).	   The	   mouse	   Slc12a1	   gene	   appears	   to	   produce	   at	   least	  
three	   variants	   as	   the	   result	   of	   the	   alternative	   election	   of	   one	   of	   three	  
mutually	  exclusive	  exons	  (Arroyo	  et	  al.	  2013;	  Markadieu	  and	  Delpire	  2014).	  
Two	  of	   these	  variants	  are	  annotated	   in	  RefSeq	  with	   the	   following	  accession	  
numbers:	   NM_183354	   [Slc12a1	   v1,	   NKCC2A	   (exon	   5)],	   NM_001079690	  
[Slc12a1	   v3,	   NKCC2F	   (exon	   6)].	   The	   third	   mouse	   NKCC2	   variant	   originally	  
named	  NKCC2B	  (exon	  4)	  (Igarashi,	  et	  al.	  1995)	  has	  yet	  to	  be	  referenced	  in	  the	  
database	  (Figure	  6B).	  	  
Chloride	  uptake	  mechanisms	  and	  insulin	  secretion	  
After	  the	  initial	  functional	  demonstration	  of	  Na+K+2Cl–	  cotransport	  in	  
ß-­‐cells	   by	   Sandström	   &	   Sehlin	   (Sandstrom	   and	   Sehlin	   1987),	   molecular	  
studies	   determined	   the	   identity	   of	   this	   cotransport	   system	   in	   ß-­‐cells	   as	  
NKCC1	  (Majid	  et	  al.	  2001).	  At	  that	  time,	  NKCC2	  was	  assumed	  exclusive	  of	  the	  
kidney	  and	  its	  presence	  was	  not	  evaluated	  (Majid	  et	  al.	  2001).	  It	  was	  not	  until	  
2012	  when	  NKCC2	  splice	  variant	  A	  was	  cloned	  from	  two	  rat	  ß-­‐cell	  lines	  (INS-­‐
1E	  and	  RIN-­‐5mF)	  (Alshahrani	  et	  al.	  2012)	  and	  subsequently	  found	  in	  rodent	  







Figure 6. The Slc12a2 (NKCC1) and Slc12a1 (NKCC2) isoforms and splice variants.  A. 
Represented are NKCC1a and  NKCC1b splice variants differing in the sequence encoded 
by the 21st exon depicted in red. B. Three of the several known NKCC2 splice variants are 
represented. They differ by the inclussion of mutually exclusive exons depicted in red (exon 
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islets,	   that	   the	   participation	   of	   this	   cotransporter	   in	   insulin	   secretion	   was	  
suggested.	  Indeed,	  bumetanide	  impaired	  insulin	  responses	  from	  WT	  islets	  or	  
mice	   lacking	   NKCC1	   (NKCC1-­‐KO)	   suggesting	   that	   bumetanide-­‐sensitive	  
mechanisms	   different	   from	   NKCC1	   are	   operative	   in	   NKCC1-­‐KO	   islets	  
(Alshahrani	   and	   Di	   Fulvio	   2012).	   Notably,	   NKCC1-­‐KO	   mice	   exhibited	  
exaggerated	   insulin	   responses	   to	   glucose	   associated	   with	   flat	   glucose	  
tolerance	  curves,	   further	  suggesting	  that	  NKCC1	  is	  not	  necessary	  for	  insulin	  
secretion	   and	   that	  NKCC2,	   present	   in	   the	   islet,	  may	  not	   adequately	   replace	  
NKCC1	   function.	   This	   is	   intriguing	   inasmuch	   as	   NKCC2	   constitutively	  
increases	  net	   Cl–	   influx	   in	   cells	  without	   changing	   cell	   volume	   (Zeuthen	   and	  
Macaulay	   2012)	   and	   ß-­‐cells	   lacking	   NKCC1	   are	   significantly	   shrunken	  
(Alshahrani	   and	  Di	   Fulvio	   2012).	   This	   suggests	   the	   possibility	   that	   [Cl–]i	   in	  
NKCC1-­‐KO	  ß-­‐cells	  might	  be	  kept	  within	  normal	  ranges	   i.e.,	  ~40	  mM	  or	  even	  
higher	   as	   a	   consequence	   of	   constitutive	   NKCC2	   function,	   but	   overall	  
decreased	  as	  per	  unit	  of	  ß-­‐cell	  mass,	  which	  in	  turn	  is	  increased	  in	  NKCC1-­‐KO	  
mice	  relative	  to	  WT	  (Alshahrani	  and	  Di	  Fulvio	  2012).	  In	  addition,	  absence	  of	  
NKCC1	   might	   impair	   the	   ability	   of	   ß-­‐cells	   to	   respond	   appropriately	   to	  
changes	  in	  cell	  volume	  induced	  by	  glucose	  metabolism.	  	  	  
Although	  the	  mechanisms	  involved	  in	  insulin	  secretion	  in	  response	  to	  
glucose	  in	  NKCC1-­‐KO	  mice	  are	  not	  fully	  understood,	  it	  is	  important	  to	  keep	  in	  
mind	   that	   plasma	  membrane	   depolarization	   is	   not	   exclusively	   achieved	   by	  
closure	   of	   KATP	   channels	   and	   that	   glucose	   homeostasis	   in	   turn	   is	   finely	  
regulated	   not	   only	   by	   insulin,	   but	   also	   by	   glucagon,	   which	   might	   be	   de-­‐
regulated	  in	  NKCC1-­‐KO	  mice.	  Further,	  absolute	  global	  absence	  of	  NKCC1	  in	  ß-­‐
cells,	  for	  instance,	  may	  set,	  up-­‐regulate,	  down-­‐regulate,	  organize,	  establish	  or	  
generate	  alternative	  regulatory	  routes	  which	  may	  eventually	  have	  an	  impact	  
in	   overall	   islet	   physiology.	   Clearly,	   additional	   experiments	   are	   needed	   to	  
elucidate	  the	  mechanisms	  of	  insulin	  secretion	  in	  islets	  lacking	  NKCC1.	  	  
Diuretics	  and	  insulin	  secretion	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"Loop	   diuretics	   also	   can	   cause	   (...)	   hyperglycemia	   (infrequently	  
precipitating	   diabetes	  mellitus)...",	   [quoted	   from	   Edwin	   Jackson,	   Chapter	   28,	  
Diuretics,	  p753	  (Goodman,	  et	  al.	  2006)]	  
As	   mentioned	   earlier,	   NKCCs	   are	   sensitive	   to	   furosemide	   and	  
bumetanide	   (BTD)	   (Haas	   and	   McManus	   1983),	   and	   probably	   other	   loop	  
diuretics	   including	   azosemide,	   torasemide,	   etacrinic	   acid,	   etozoline,	  
muzolimine,	   piretanide	   or	   tienilic	   acid.	   Thiazides,	   however,	   are	   a	   different	  
group	  of	  diuretics	  which	  main	   targets	  are	  NCCs	   (Hilal-­‐Dandan,	  et	  al.	  2011).	  
Many	   studies	   tested	   the	   effect	   of	   thiazides	   on	   carbohydrate	  metabolism	   in	  
humans	  and	  animal	  models.	  The	  notion	  that	  all	  diuretics	  may	  cause	  diabetes	  
sparked	   after	   a	   single	  manuscript	   published	   soon	   after	   the	   introduction	   of	  
this	   loop	   diuretic	   in	   the	   clinics	   in	   late	   50's	   (Wilkins	   1959).	   Subsequently,	  
textbooks	   dedicated	   to	   the	   study	   of	   hypertension	   discussed	   the	   impact	   of	  
thiazides	  in	  diabetes	  and	  cautioned	  about	  their	  use	  in	  hypertensive	  patients	  
(see	   Finnerty	   F.A.:	   Discussion	   of	   Special	   Problems	   in	   Therapy	   of	  
Hypertension.	   Hahnemann	   Symposium	   on	   Hypertensive	   Diseases	   1958:	  
Hypertension,	   edited	   by	   Moyer	   J.F.,	   Philadelphia:	   W.B.	   Saunders	   Company,	  
1959,	   p653;	   and	   Freis	   E.:	   Discussion	   of	   Special	   Problems	   in	   Therapy	   of	  
Hypertension,	   Hahnemann	   Symposium	   on	   Hypertensive	   Diseases,	   1958:	  
Hypertension	  1959,	  p652).	  	  
The	  earliest	   reports	   relating	   thiazides	   and	   carbohydrate	  metabolism	  
showed	  impaired	  glucose	  tolerance	  and	  even	  glycosuria	  in	  some	  but	  not	  all	  of	  
a	  variety	  of	  patient	  groups	  treated	  in	  different	  ways	  with	  the	  diuretic	  [briefly	  
summarized	   in	   (Giugliano,	   et	   al.	   1980)].	   For	   instance,	   Goldner	   and	  
collaborators	   treated	  20	  patients	  with	  no	  clinical	  manifestations	  of	  diabetic	  
and	   20	   diabetic	   patients	   with	   oral	   thiazide	   derivatives.	   Contrary	   to	   initial	  
expectations,	   thiazides	   did	   not	   precipitate	   glucose	   intolerance	   or	  
hyperglycemia	   in	  non-­‐diabetic	  patients,	  whereas	  30%	  of	   the	  diabetic	  group	  
showed	   hyperglycemia	   and	   glycosuria	   (Goldner,	   et	   al.	   1960).	   In	   1961,	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Zatuchni	  &	  Kordasz	  demonstrated	  that	  thiazides	  elevated	  glycemia	  in	  56%	  of	  
25	   patients	   suffering	   various	   cardiac	   conditions	   (Zatuchni	   and	   Kordasz	  
1961).	   The	   diabetogenic	   long-­‐term	   effects	   of	   benzothiadiazines	   were	  
suggested	   later	   on	   by	   Wolf	   and	   collaborators	   in	   non-­‐obese	   and	   obese	  
hypertensive	   patients	   with	   family	   history	   of	   diabetes	   (Wolf,	   et	   al.	   1963).	  
Thirteen	  years	  later,	  however,	  Lewis	  and	  coworkers	  demonstrated	  that	  two	  
years	   of	   thiazide	   administration	   to	   normal	   subjects	   did	   not	   result	   in	  
hyperglycemia,	   which	   could	   only	   be	   observed	   after	   six	   years	   of	   treatment	  
(Lewis,	  et	  al.	  1976).	  	  	  
The	   impairment	   of	   glucose	   tolerance	   observed	   after	   thiazide	  
treatment	   of	   some	   but	   not	   all	   subjects	   studied	   is	   still	   controversial.	   In	  
particular	   within	   the	   context	   of	   the	   observation	   that	   K+	   replenishment	  
prevented	   glucose	   intolerance	   in	   patients	   chronically	   treated	   with	  
chlorothiazide.	   Indeed,	   hypokalemia,	   a	   common	   finding	   in	   thiazide-­‐treated	  
patients	  was	  originally	  considered	  as	  the	  cause	  of	  hyperglycemia	  in	  patients	  
chronically	   treated	   with	   thiazides	   (Rapoport	   and	   Hurd	   1964;	   Seltzer	   and	  
Allen	   1969).	   These	   observations,	   together	   with	   those	   of	   Cornish	   and	  
collaborators	   in	   1961,	   who	   demonstrated	   morphological	   and	   pathological	  
changes	   induced	  by	  chronic	   thiazide	  treatment	   in	   the	  pancreas	  of	  21	  out	  of	  
300	  mice	  (Cornish,	  et	  al.	  1961),	  precipitated	  the	  conclusion	  that	  thiazides,	  a	  
strong	  inhibitor	  of	  NCCs	  and	  other	  Cl–	  transporters	  (Leviel,	  et	  al.	  2010)	  may	  
cause	  diabetes.	   Interestingly,	   that	  concept	  was	  also	  extended	  to	   furosemide	  
and	   later	   to	   BTD	   developed	   in	   1964	   and	   1971,	   respectively	   (Feit	   1971;	  
Ingram	  1964),	   in	   spite	  of	   the	   fact	   that	   few	  studies	  dealt	  with	   this.	  The	   first	  
one,	   for	   instance,	   performed	   in	   1966	   showed	   that	   furosemide	   impairs	  
glucose	  tolerance	  after	  three-­‐month	  administration	  of	  the	  diuretic	  to	  normal	  
and	   hypertensive	   diabetic	   patients	   in	   response	   to	   systemic	   injection	   of	   the	  
sulphonylurea	   tolbutamide,	   a	   KATP	   channel	   inhibitor	   (Jackson	   and	   Nellen	  
1966).	   The	   second	   study	   done	   6	   years	   later,	   demonstrated	   no	   impact	   of	  
furosemide	   or	   the	   newly	   developed	   BTD	   on	   glycemia	   in	   4	   normal	   subjects	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treated	   with	   different	   concentrations	   of	   the	   diuretics	   at	   4	   days	   intervals	  
(Asbury,	  et	  al.	  1972).	  The	  third	  study	  came	  in	  1980	  demonstrating	  that	  BTD	  
administered	   acutely	   and	   systemically	   did	   not	   change	   basal	   or	   stimulated	  
insulin	  secretion,	  and	  did	  not	  change	  glucose	  tolerance	  after	  ten	  days	  of	  BTD	  
administration	   in	  14	  normal	  subjects	  (Giugliano	  et	  al.	  1980).	  The	  next	  year,	  
Robinson	   and	   collaborators	   wrote	   in	   the	   abstract	   of	   their	   paper:	   "Glucose	  
tolerance	   was	   significantly	   improved	   with	   bumetanide	   but	   not	   with	  
furosemide",	  at	   least	   in	  eleven	  healthy	   individuals	  treated	  with	  the	  diuretics	  
for	  8	  days	  or	  T2DM	  patients	  for	  6	  weeks	  (Robinson,	  et	  al.	  1981).	  Soon	  after	  
these	  publications,	  Hermansen	  and	  collaborators	  demonstrate	  that	  thiazides	  
actually	   increased	   basal	   insulin,	   glucagon	   and	   somatostatin	   release	   from	  
perfused	  isolated	  dog	  pancreas	  whereas	  BTD	  did	  not	  have	  a	  significant	  effect	  
on	   the	   same	   parameters	   (Hermansen,	   et	   al.	   1985).	   When	   taken	   together,	  
these	   results	   indicate	   that	   the	   impact	   of	   diuretics	   on	   glucose	   homeostasis	  
depends	  on	   the	  population	   studied	  and	   the	  diuretic	  used.	   In	   fact,	  BTD	  may	  
actually	  have	  beneficial	  potential	  rather	  than	  being	  diabetogenic!	  
The	   "inconsistency"	   of	   the	   effects	   of	   diuretics	   on	   carbohydrate	  
metabolism,	   as	   referred	   to	   in	   Flamenbaum	   &	   Friedman	   (Flamenbaum	   and	  
Friedman	  1982),	  became	  more	  problematic	  when	  Sandström	  demonstrated	  
that	  a	  high	  single	   intraperitoneal	   (ip)	  dose	  of	  BTD	  (100	  mg/kg)	   transiently	  
increases	  glycemia	  and	  impairs	  glucose	  tolerance	  in	  mice	  (Sandstrom	  1988)	  
and	   that	   hydrochlorotiazide	   inhibits	   insulin	   secretion	   directly	   from	   the	  
mouse	  islet	  by	  a	  mechanism	  not	  related	  to	  Cl–	  but	  to	  Ca2+	  fluxes	  (Sandstrom	  
1993),	   thus	   indicating	   that	   NCC,	   the	   main	   target	   of	   thiazides	   cannot	   be	  
involved	   in	   the	   effects	   of	   the	   thiazide.	  Notably,	   the	   response	   to	   50-­‐100	  mg	  
BTD/kg	   in	   mice	   was	   not	   different	   from	   that	   of	   200	   mg	   furosemide/kg	  
observed	   in	   earlier	   experiments	   (Asbury	   et	   al.	   1972;	   Cohen,	   et	   al.	   1976)	  
consistent	  with	  the	  idea	  that	  BTD	  is	  ~40	  times	  more	  potent	  than	  furosemide	  
(Hilal-­‐Dandan	   et	   al.	   2011).	   Therefore,	   when	   taken	   together	   these	   results	  
suggest	   that	   NKCCs	   might	   regulate	   insulin	   secretion,	   a	   concept	   that	   was	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supported	   in	   subsequent	   experiments	   in	   vitro,	   as	   discussed	   earlier	   in	   this	  
Introduction,	  but	  mostly	  when	   the	  effects	  of	  BTD	  were	   tested	  acutely	   (Best	  
2005;	  Sandstrom	  1990;	  Sandstrom	  and	  Sehlin	  1988c).	  
Acute	  versus	  long-­‐term	  effects	  of	  BTD	  and	  furosemide	  on	  NKCCs	  
Interestingly	   enough,	   most	   of	   our	   knowledge	   regarding	   the	  
pharmacological	  or	  functional	  properties	  of	  NKCCs	  comes	  from	  experiments	  
performed	   in	  vitro	  wherein	  acute	  actions	  of	  diuretics	  were	   studied	   (Gamba	  
2005).	   In	  a	  more	   realistic	   clinical	   scenario,	  diuretics,	   in	  particular	  BTD	  and	  
furosemide	  are	  administered	  chronically	  and	  as	  expected,	  the	  pharmacologic	  
outcome	   of	   such	   administration	   is	   increased	   diuresis	   (Roush,	   et	   al.	   2014).	  
This	  clinically	  relevant	  and	  easy	  to	  observe	  effect	  of	  BTD	  is	  the	  consequence	  
of	   its	  concentration	   in	   the	   tubules	  of	   the	  kidney	  and	   inhibition	  of	  NKCC2	   in	  
the	  TALH	  (Schlatter,	  et	  al.	  1983).	  However,	  chronic	  treatment	  with	  BTD	  may	  
impact	   gene	   expression	   (Rizzo,	   et	   al.	   2004).	   In	   addition,	  NKCC1	   is	   not	   only	  
the	  most	   sensitive	   target	   of	   BTD	   but	   also	   a	   widely	   expressed	   one	   (Gamba	  
2005).	  Therefore,	  several	  questions	  arise:	  What	  is	  the	  long-­‐term	  effect	  of	  BTD	  
on	   the	   ubiquitously	   expressed	   NKCC1?	   What	   effect	   would	   long-­‐term	   BTD	  
have	   if	  administered	  at	   low	  doses?	  Would	   long-­‐term	  administration	  of	  BTD	  
impair	  insulin	  secretion?	  
The	   answer	   to	   the	   first	   question	   is	   unknown,	   but	   assumed	   to	   be	  
negligible	  (Loscher,	  et	  al.	  2013)	  as	  BTD	  is	  highly	  ionized	  at	  physiological	  pH	  
and	  ~90%	  of	  it	  circulates	  bound	  to	  plasma	  proteins	  (Cohen	  et	  al.	  1976).	  The	  
answer	   to	   the	   second	   question	   is	   partial	   but	   encouraging	   inasmuch	   as	   low	  
doses	   of	   BTD	   are	   used	   to	   treat	   neonatal	   seizures	   and	   other	   GABAergic	  
disorders	   where	   central	   neuronal	   NKCC1	   is	   thought	   to	   play	   a	   major	   role	  
(Ben-­‐Ari	   2012;	  Cotton,	   et	   al.	   2012;	  Hochman	  2012;	  Kahle	   and	  Staley	  2008;	  
Pressler	  and	  Mangum	  2013;	  Walcott,	  et	  al.	  2012).	  As	   for	  the	  third	  question,	  
the	  previous	   section	  provided	   the	  notion	   that	   the	   impact	  of	  BTD	  and	  other	  
diuretics	  on	  carbohydrate	  metabolism	   is	  clearly	   inconsistent	  and	   that	  more	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research	  needs	   to	  be	  done	   in	  order	   to	   improve	  our	  knowledge.	  This	  Thesis	  
aims	  to	  that.	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  HYPOTHESIS	  AND	  SPECIFIC	  AIMS	  
Hypothesis	  
Long-­‐term	  BTD	  does	  not	  impair	  insulin	  secretion	  due	  to	  BTD-­‐induced	  
changes	  in	  NKCC	  expression	  in	  ß-­‐cells.	  	  
	  	  
Specific	  aims	  
To	   determine	   the	   long-­‐term	   effect	   of	   BTD	   on	   insulin	   secretion	   in	   ß-­‐
cells	  
To	  correlate	  NKCC	  expression	  and	  total	  chloride	  uptake	  in	  ß-­‐cells	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MATERIALS	  AND	  METHODS	  
Antibodies	  
The	   primary	   antibodies	   used	   in	   our	   experiments	   are	   indicated	   in	  
Table	   1.	   Conjugated	   secondary	   antibodies	   for	   Western	   blotting	   and	  
immunofluorescence	   applications	   were	   from	   Jackson	   Immunoresearch	  
Laboratories,	   Inc.	   (West	   Grove,	   PA).	   Stocks	   of	   these	   antibodies	   were	  
immediately	   prepared	   upon	   arrival	   by	   adding	   an	   equal	   volume	   of	   glycerol	  
(Affimetrix/USB,	  Cleveland,	  OH)	   to	  avoid	   freezing	  and	   thawing	  cycles	  while	  
storing.	   Aliquots	   of	   the	   stocks	   were	   stored	   at	   −80ºC	   whereas	   working	  
aliquots	   were	   kept	   at	   −20ºC.	   Secondary	   antibodies	   for	   Western	   blotting	  
applications	   were	   dissolved	   in	   appropriate	   volume	   of	   water	   upon	   arrival,	  
then	  fractionated	  and	  stored	  at	  −80ºC.	  Working	  aliquots	  of	  these	  antibodies	  
were	  kept	  at	  −20ºC	  after	  diluting	  with	  glycerol	  1:1	  (v/v).	  
Cell	  culture	  
The	  mouse	   insulinoma	   ß-­‐cell	   line	  MIN6	  was	   kindly	   provided	   by	   Dr.	  
Jun-­‐Ichi	   Miyazaki	   (University	   of	   Kumamoto,	   Medical	   School,	   Kumamoto,	  
Japan)	  (Miyazaki,	  et	  al.	  1990).	  We	  selected	  this	  pancreatic	  ß-­‐cell	  line	  for	  our	  
studies	  because	  their	  insulin	  response	  to	  physiologic	  glucose	  closely	  matches	  
that	   of	   primary	  ß-­‐cells	   (Ishihara,	   et	   al.	   1993).	   In	   addition,	   this	   cell	   line	   has	  
been	   thoroughly	   characterized	   at	   the	   functional	   and	   molecular	   levels	   by	  
numerous	  researchers	  throughout	  the	  years	  and	  is	  the	  most	  commonly	  used	  
ß-­‐cell	   line	   to	   study	   mechanisms	   of	   insulin	   secretion	   (Skelin,	   et	   al.	   2010).	  
Adherent	  MIN6	  ß-­‐cells	  were	  cultured	  essentially	  as	  described	  (Ishihara	  et	  al.	  
1993;	  Miyazaki	  et	  al.	  1990).	  In	  brief,	  MIN6	  ß-­‐cells	  were	  grown	  in	  Dulbecco's	  
modified	   Eagle's	   medium	   (DMEM)	   containing	   11	   mM	   glucose,	   4	   mM	   L-­‐
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Antigen Host/isotype Provider Application Dilution
NKCC1 human chicken IgY Thermo WB 1:500
IF 1:500
NKCC2 human goat IgG Everest WB 1:250
NKCC2 human rabbit IgG Fitzgerald IF 1:200
ß-actin human mouse IgM DSHB WB 1:1000
Insulin human guinea pig IgG Cell Marque IF 1:500
Glucagon porcine goat IgG Abcam IF 1:250
HRP-conjugated IgY donkey Jackson WB 1:1000
Cy3-conjugated IgY donkey Jackson IF 1:500
AF488-conjugated IgY donkey Jackson IF 1:500
HRP-conjugated goat IgG donkey Jackson WB 1:500
AF488-conjugated goat IgG donkey Jackson IF 1:500
Cy3-conjugated rabbit IgG donkey Jackson IF 1:500
HRP-conjugated mouse IgM Rabbit Jackson WB 1:5000
DyLight-conjugated guinea pig IgG donkey Jackson IF 1:500












NKCC1(T4) human mouse IgM DSHB WB 1:250
NKCC1 human chicken IgY Thermo
HRP-conjugated mouse IgG goat Jackson WB 1:1000
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glutamine,	  1	  mM	  sodium	  pyruvate,	  10	  %	  (v/v)	  fetal	  bovine	  serum	  (FBS),	  100	  
IU/ml	  penicillin	  and	  100	  μg/ml	  streptomycin	  or	  100X	  antimycotic-­‐antibiotic	  
mix.	  Cells	  were	  grown	  in	  5	  %	  CO2	  at	  37ºC	  and	  media	  changed	  every	  3	  days	  
until	   desired	   confluence	  was	   reached.	   Cells	  were	   cultured	   in	   75	   cm2	   flasks	  
(T75)	   treated	   for	   cell	   culture	  and	  used	  until	  passage	  30.	  Although	  MIN6	  ß-­‐
cells	  have	  been	  used	  at	  higher	  passages	  with	  satisfactory	  results	  (Cheng,	  et	  al.	  
2012),	   the	   passage	   limit	   of	   30	  was	   chosen	   to	   avoid	   potential	   genotypic	   or	  
phenotypic	   changes.	   Cells	   were	   propagated	   by	   enzymatic	   digestion	   of	   the	  
extracellular	  matrix	  by	  using	  3	  ml	  0.05	  %	  (w/v)	  trypsin	  supplemented	  with	  
0.53	  mM	  EDTA	  for	  5	  min	  at	  room	  temperature.	  Cell	  detachment	  was	  followed	  
under	   an	   inverted	   microscope	   until	   all	   cells	   were	   detached.	   Trypsin-­‐
mediated	   digestion	   was	   inhibited	   by	   adding	   culture	   media	   fully	  
supplemented.	   The	   total	   number	   of	   detached	   cells	   was	   then	   used	   to	   seed	  
either	   four	   T75	   flasks	   or	   the	   appropriate	   number	   of	   6/12-­‐well	   plates	   to	  
perform	  experiments.	  
Kidney	   fibroblast	   COS7	   cells	   (ATCC,	   Manassas,	   VA)	   were	   grown	   as	  
control	   cells	   for	   the	   standardization	   of	   Cl–	   fluxes	   and	   gene	   expression	  
analyses	   considering	   that	   this	   cell	   line	   has	   been	   extensively	   characterized	  
and	  are	  relatively	  simple	  to	  maintain.	  COS7	  cells	  were	  maintained	   in	  6-­‐well	  
plates	  (BioLite,	  Thermo	  Scientific)	  in	  fully	  supplemented	  DMEM	  in	  a	  5%	  CO2	  
incubator	   at	   37ºC.	   COS7	   cells	   depleted	   of	   endogenous	   NKCC1	   or	   NKCC2	  
expression	   (COS7shNKCC1	   and	   COS7shNKCC2,	   respectively)	   and	   control	   cells	  
(COS7shControl)	   were	   generated	   as	   we	   have	   recently	   described	   in	   detail	  
elsewhere	   (Singh	   et	   al.	   2014).	   These	   cells	   were	   cultured	   in	   fully	  
supplemented	  DMEM	  plus	  the	  continuous	  presence	  of	  2.5	  µg/ml	  puromycin.	  	  
Mice	  
The	  use	  of	  mice	  for	  our	  experiments	  was	  approved	  by	  the	  Institutional	  
Animal	  Care	  and	  Use	  Committee	  of	  WSU-­‐BSoM.	  Mice	  had	  ad	  libitum	  access	  to	  
a	   standard	   chow	  diet	   and	  water	   and	  were	   housed	   under	   12-­‐12	   hour	   light:	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darkness	  cycles.	  Wild-­‐type	  mice	  (WT,	  C57BL/6J	  genetic	  background)	  of	  both	  
sexes	   aging	   4-­‐6	  weeks	  were	   used	   in	  most	   of	   our	   experiments.	   These	  mice	  
were	   routinely	   generated	   in	   our	   Animal	   Facility	   by	   crossings	   genetically	  
engineered	   mice	   harboring	   a	   single	   functional	   allele	   of	   NKCC2A	  
(heterozygous,	   NKCC2-­‐HE)	   (Figure	   7A).	   These	   breeders	   were	   kindly	  
provided	  by	  Dr.	  Hayo	  Castrop	  (University	  of	  Regensburg)	  (Oppermann,	  et	  al.	  
2007).	   To	   identify	   WT,	   HE	   or	   KO	   mice,	   we	   took	   advantage	   of	   the	   genetic	  
strategy	   followed	   to	   create	   those	   breeders.	   Briefly,	   premature	   stop	   codons	  
were	  introduced	  in	  the	  96	  bp	  exon	  5	  (exon	  A)	  of	  the	  Slc12a1	  gene	  in	  the	  form	  
of	   a	  97	  bp	  FLAG-­‐tagged	   sequence.	  The	  new	   targeted	  exon	  A	  of	  192	  bp	  and	  
flanking	   sequences	   was	   used	   to	   design	   primers	   for	   the	   polymerase	   chain	  
reaction	  (PCR)	  to	  determine	  the	  genotypes	  of	  mice	  in	  our	  colony	  (Figure	  7B).	  
The	   genotyping	   primers	   recognizing	   flanking	   intronic	   sequences	   5'	   and	   3'	  
exon	   A	   are	   indicated	   in	  Table	   2.	   The	   primer	   set	   is	   predicted	   to	   amplify	   a	  
single	  band	  of	  206	  bp	  or	  302	  bp	  from	  genomic	  DNA	  obtained	  from	  WT	  or	  KO	  
mice,	   respectively,	   or	   the	   two	   bands	   in	   the	   case	   of	   heterozygous	   mice	   i.e.,	  
those	   harboring	   both	   alleles:	   WT	   and	   KO	   (Figure	   7B).	   The	   procedure	   for	  
genotyping	  mice	  was	  developed	  and	  set	  up	  in	  our	  laboratory	  by	  Victor	  Otaño-­‐
Rivera	   (Undergraduate	   STREAMS	   Student)	   and	   Amma	   Boayke	  
(Undergraduate	   HONORS	   Student)	   and	  was	   based	   on	   the	   original	   protocol	  
written	  by	  Glenn	  Travis	  in	  Laboratory	  of	  Molecular	  Systematics,	  Smithsonian	  
Institution.	   Washington,	   DC	   20560,	   and	   the	   protocols	   of	   Walsh	   and	  
collaborators	   (Walsh,	   et	   al.	   1991)	   and	   the	   one	   described	   by	   Morin	   &	  
Woodruff	   in	  Paternity	  exclusion	  using	  multiple	  hypervariable	  microsatellite	  
loci	  amplified	  from	  nuclear	  DNA	  of	  hair	  cells.	  Pages	  63-­‐81	  in	  RD	  Martin,	  AF	  
Dixon	  &	  EJ	  Wickings	  (eds).	  Paternity	  in	  primates:	  genetic	  tests	  and	  theories.	  
Basel,	  Karger	  1992.	  	  
Mice	   tissue	   samples	   were	   placed	   in	   tubes	   containing	   100	   µl	   10%	  
chelex	   resin	   (Sigma	   C7901)	   and	   centrifuged	   30	   secs	   at	   12,000	   rpm	   in	   a	  
centrifuge	  (Sorvall	  Legend	  Micro	  21R	  centrifuge,	  Thermo	  Scientific)	  to	  collect	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Figure 7. The NKCC2A mice colony and genotyping. A. 
Breeding strategy followed to produce mice lacking one 
(heterozygous, HE) or  two alleles (knock-out, KO) of the NKCC2A 
transgene or wild-type (WT) mice. B. Genotyping strategy to 
determine HE, KO or WT genotypes in NKCC2A mice. On top, 
represented is exon A WT (red) of the NKCC2 gene, the two 
flanking primers used for PCR and the targeted exon A including 
additional 97 bp inserted (Flag-Stop). PCR performed with the 
indicated primers (red arrowheads) are predicted to produce a 
single fragment of 205 bp (WT), 302 bp (KO) or both (HE).
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Table 2
Primer set Sense Antisense Amplicon/s (bp) Species Application
NKCC1-599a/551b GAAGACAAGCTATGAAAGAGATGTC CCAGACATCTATAGTATTCTTCCCTTG 599a / 551b mouse RT-PCR
NKCC1-501a/453a CTAAAGGAAGGACTGGATATATCACAC GACCATGATATCGGAGAAGTCTATTC 501a / 453b mouse RT-PCR
NKCC1-515 CTCTATGTAAGGACAATATCTACCCAG GTTTGGAGAACCTGTCATTACAAG 515 mouse RT-PCR
NKCC2-700 GCGGAAAACTTTGGGCCAAGCTTCACAG CCGGCCTCCATCCTGGCGATTTG 700 mouse RT-PCR
NKCC2-643 GCTTATCCCATATATCTTGACTCTCAG AGGTTAGTCTCCAGAGGTTTGTATA 643 mouse RT-PCR
NKCC2-641 ATCTAGCTATCGGGTCATCTAAAAC GTCATGTCTTCTTCCTTGTTTTCTG 641 mouse RT-PCR
NKCC2-600 GACTTCTCAAGATGTCAACACGAG GTCTAAAGCACTCACATAGGACAG 600 mouse RT-PCR
NKCC2-429 CTGTCCTATGTGAGTGCTTTAGAC TATGATTCCCACGTAGTTCTCCAG 429 mouse RT-PCR
NKCC2-350 CAGAGGCTTCTTTAACTACCAAGC GTTGACATCTTGAGAAGTCGTAGC 350 mouse RT-PCR
GAPDH-555 GTGAAGGTCGGAGTCAACGGATTT AGTCTTCTGGGTGGCAGTGAT 555 human RT-PCR
C/D TGCAGGAGTGGGTAGTCCAA CCGTAGCATGTGACGTGGAT 302 KO/206 WT mouse Genotyping
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the	  tissue	  sample	  at	  the	  bottom	  of	  the	  tubes.	  Then,	  tubes	  were	  incubated	  at	  
100_ºC	   for	   20	   minutes	   with	   casual	   swirl.	   The	   PCR	   amplification	   mixture	  
consisted	   in	   (for	   each	   sample):	   0.25	   µl	   Taq	   DNA	   polymerase	   (GenScript	  
E00007),	   2.5	   µl	   10X	   Taq	   buffer	   (Gen	   Script	   B0005),	   0.5	   µl	   dNTPs	   10	   mM	  
(USB/Affimetrix	  #77119),	  0.25	  µl	  each	  primer,	  21	  µl	  of	  nuclease-­‐free	  water	  
(Hyclone	   sh30529.02)	   and	   2	   µl	   DNA	   samples	   (or	   2	   µl	   water	   as	   negative	  
control)	   set	   in	   a	   thin-­‐walled	   PCR	   tube	   (Fisher	   14230205).	   Then,	   PCR	   was	  
performed	   in	  a	   thermal	  cycler	   (Bio	  Rad,	  BioRad	  Hercules,	  CA)	   for	  40	  cycles	  
with	  the	  usual	   thermal	  settings.	  The	  products	  of	  PCR	  were	  then	  resolved	  in	  
2%	   agarose	   (Axygen	   AX-­‐LE120060)	   gels	   prepared	   in	   Tris-­‐Acetate-­‐EDTA	  
buffer	   (Teknova,	   T1346)	   and	   visualized	   by	   using	   ethidium	   bromide	  
(USB/Affimetrix	  #75809).	  The	  molecular	  weights	  of	   the	  PCR	  products	  were	  
compared	   against	   a	   100	   bp	   DNA	   ladder	   (Fermentas	   SM0243)	   (see	   Figure	  
7B).	  
Islet	  preparations	  
WT	   islets	   were	   isolated	   following	   the	   method	   of	   Carter	   and	  
collaborators	   (Carter,	   et	   al.	   2009)	   and	   under	   the	   supervision	   of	   Dr.	   Lydia	  
Aguilar-­‐Bryan’s	  team	  (Pacific	  Northwest	  Diabetes	  Research	  Institute,	  Seattle,	  
WA,	   USA).	   Briefly,	   mice	   were	   euthanized	   with	   compressed	   CO2.	   Then,	  
abdomen	  was	  opened	  and	  pancreas,	   liver	  and	  duodenum	  were	   located	  and	  
then	   bile	   duct	   was	   exposed.	   Bile	   duct	   was	   closed	   tightly	   using	   a	   piece	   of	  
thread	  at	  the	  conjunction	  with	  duodenum.	  A	  hole	  in	  the	  bile	  duct	  was	  poked	  
using	  27G*1/2	  surflo-­‐winged	  infusion	  set	  (Terumo	  SV*27EL)	  that	  connected	  
with	   a	   10	  ml	   syringe	   containing	   3	  ml	   of	   collagenase	   solution	   (Vorthington	  
#4210	  at	  4.3	  mg/ml	  in	  DMEM	  medium).	  Then,	  the	  pancreas	  was	  inflated	  with	  
collagenase	   solution	   gently	   and	   slowly.	   After	   inflation	   process	   was	  
performed,	   the	   pancreas	   was	   cut	   starting	   from	   the	   side	   close	   to	   the	  
duodenum	   toward	   the	   small	   intestines	   and	   then	   close	   to	   the	   stomach	   and	  
colon.	   Then,	   the	   pancreas	  was	   grabbed	   and	   placed	   in	   a	   new	   15	  ml	   conical	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tube	  containing	  ~2	  ml	  collagenase	  solution	  to	  perform	  the	  digestion	  process	  
as	  follows:	  the	  tube	  was	  placed	  in	  the	  water	  bath	  (37_ºC)	  for	  10	  min	  and	  then	  
shaken	   firmly	   and	   vigorously	   ~12	   times.	   After	   the	   digestion	   process	   was	  
completed	  i.e.,	  no	  tissue	  chunks	  were	  visible,	  5	  ml	  of	  cold	  DMEM	  medium	  was	  
added	   to	   stop	   digestion	   and	   then	   the	   tube	   centrifuged	   3	  min	   at	   1000	   rpm.	  
The	  supernatant	  was	  discarded	  and	   the	  pellet	   re-­‐suspended	   in	  3	  ml	  DMEM	  
medium.	   Islets	  were	   then	  purified	  by	   filtration	   through	  0.22	  µm	  pore	   filter	  
(Millex	   SLGP033RS)	   by	   centrifugation	   for	   3	   min	   at	   1000	   rpm.	   The	   pellet	  
obtained	   and	   containing	   islets	   was	   used	   for	   protein/RNA	   extraction	   or	  
culture	   in	  RPMI/10	  %	  FBS	  medium.	   Islets	  usually	   attached	   in	  6-­‐well	  plates	  
for	  3	  days	  at	  37_ºC/5	  %	  CO2	  before	  functional	  experiments.	  	  
In	   some	   occasions	   were	   islet	   yield	   was	   predicted	   low,	   islets	   were	  
purified	  by	  Ficoll	  gradient	  centrifugation.	  Briefly,	  removed	  pancreases	  were	  
washed	  twice	  with	  ice-­‐cold	  DMEM	  and	  then	  finely	  chopped	  by	  using	  surgical	  
blades.	   Chopped	   tissues	   were	   transferred	   to	   tubes	   containing	   2	   ml	   of	  
collagenase	  solution	  prepared	  as	  indicated	  above,	  incubated	  in	  water	  bath	  at	  
37_ºC	   for	   10	   min	   and	   shaken	   firmly	   and	   vigorously	   ~12	   times.	   After	   the	  
digestion	   process	   was	   performed,	   DMEM	   medium	   was	   added	   to	   stop	   the	  
action	  of	  collagenase	  and	  centrifuged	  at	  1000	  rpm	  for	  3	  min.	  The	  supernatant	  
was	   discarded,	   the	   pellet	   re-­‐suspended	   in	   3	   ml	   RPMI	   (Gibco	   1640)	   and	  
filtered	  through	  0.22	  µm	  pore	  filters.	  The	  filtrate	  was	  centrifuged	  at	  1000rpm	  
for	  3	  min	  and	  then	  the	  supernatant	  discarded	  (RPMI	  was	  removed	  as	  much	  
as	  possible).	  The	  pellet	  was	  re-­‐suspended	  in	  4	  ml	  Histopaque	  (Sigma	  1077)	  
using	  pipette	  4-­‐5	  times.	  Then,	  5	  ml	  RPMI	  was	  added	  slowly	  (drop	  by	  drop)	  to	  
the	  tube's	  side	  above	  Histopaque.	  To	  separate	  islets	  from	  Histopaque,	  tubes	  
were	  centrifuged	  at	  2000	  rpm	  at	  4_ºC	  without	  rotor	  brake	  and	  for	  5	  min.	  The	  
islets	  were	  then	  collected	  at	  the	  interface	  of	  Histopaque	  and	  RPMI	  and	  placed	  
in	  a	  new	  tube	  containing	  5	  ml	  of	  RPMI.	  The	  final	  islet	  pellet	  was	  obtained	  by	  
centrifugation	   3	  min	   at	   1000	   rpm.	   The	   supernatant	   was	   removed	   and	   the	  
pellet	  used	  for	  protein/RNA	  analysis	  or	  re-­‐suspended	  with	  RPMI/10	  %	  FBS	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medium	  for	  islets	  culture.	  
Protein	  Determination	  
Total	  protein	  content	  was	  estimated	  in	  control	  and	  treated	  samples	  by	  
using	  the	  Bradford	  method	  (BioRad,	  Hercules,	  CA)	  and	  relating	  the	  results	  to	  
standard	   curves	   built	   by	   using	   increasing	   concentrations	   of	   bovine	   serum	  
albumin	  (BSA,	  0-­‐5	  μg/μl).	  	  
Western	  Blotting	  
Western	  blot	  analysis	  of	  protein	  extracts	  obtained	  from	  MIN6	  ß-­‐cells	  
was	   performed	   essentially	   as	   described	   in	   detail	   elsewhere	   (Singh	   et	   al.	  
2014)	  and	  adapted	   to	  our	  experiments.	  Briefly,	  ~90%	  confluent	  MIN6	  cells	  
growing	  in	  6	  well	  plates	  were	  placed	  on	  ice	  and	  washed	  three	  times	  with	  cold	  
phosphate	  buffer	  saline	  (PBS).	  Then,	  50	  µl/well	  of	  lysis	  buffer	  (25	  mM	  Tris-­‐	  
HCl	   pH	   7.5,	   1	   mM	   EDTA	   pH	   8.0,	   1	   mM	   EGTA	   pH	   8.0,	   0.1	   %	   v/v	   β-­‐
mercaptoethanol,	  1%	  Triton	  100X,	  50	  mM	  NaF,	  150	  mM	  NaCl,	  1.5	  mM	  MgCl2)	  
were	   added.	   To	   extract	   proteins	   from	  purified	   islets	   or	   tissues	  RIPA	  buffer	  
(Teknova	  R3792)	  was	  used	  at	  a	  proportion	  of	  3	  ml	  per	  1	  g	  of	  tissue).	  All	  lysis	  
buffers	  were	  supplemented	  with	  phenylmethylsulfonyl	   fluoride	  (PMSF)	  and	  
protease/phosphatase	   inhibitors	   cocktails	   (Thermo	   Scientific	   78443)	  
composed	   of	   aprotinin,	   bestatin,	   E-­‐64,	   leupeptin,	   soldium	   fluoride,	   sodium	  
orthovanadate,	  sodium	  pyrophosphate	  and	  β-­‐glycerophosphate	  were	  added	  
in	  each	  well.	  Cell	  lysates	  were	  collected	  and	  placed	  in	  labeled	  micro-­‐tubes	  on	  
ice	   for	  ~1	   h	  with	   vortex	   every	   5	  min.	   50-­‐100	   μg	   of	   total	   protein	   in	   a	   final	  
volume	  of	  10-­‐20	  µl	  was	  mixed	  with	  equal	  amount	  of	  loading	  buffer	  (8	  %	  SDS,	  
125	  mM	  Tris-­‐HCl,	  pH-­‐	  6.8,	  20	  %	  glycerol,	  0.02%	  bromophenol	  blue,	  100	  mM	  
dithiothreitol)	  and	  boiled	  5	  min	  before	   loading	  onto	  pre-­‐casted	  Tris-­‐HEPES	  
4-­‐20	  %	  SDS-­‐PAGE	  protein	  gels	   (Thermo	  Scientific-­‐Pierce,	  Rockford,	   IL).	  Gel	  
wells	   were	   washed	   before	   loading	   samples	   by	   using	   Tris-­‐HEPES	   buffer	   to	  
eliminate	  traces	  of	  polyacrylamide	  and	  improve	  the	  electrophoretic	  mobility	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of	   proteins.	   Proteins	   were	   separated	   for	   ~1	   h	   at	   100V.	   The	   separated	  
proteins	  were	  electro-­‐transferred	  onto	  PVDF	  membranes	  (Millipore,	  MA)	  at	  
4_ºC	  for	  ~2.5	  hours	  at	  72V.	  Membranes	  were	  air-­‐dried	  and	  cut	  according	  to	  
the	  desired	  proteins	  size	  to	  allow	  immunoblotting	  with	  multiple	  antibodies.	  
For	   instance,	   the	   upper	   part	   of	   the	   membrane	   containing	   proteins	   of	  
molecular	  weight	  (MW)	  ranging	  from	  70-­‐260	  kDa	  was	  immunblotted	  against	  
NKCC1	  (130-­‐170	  kDa)	  or	  NKCC2	  (120-­‐160	  kDa)	  whereas	  the	  bottom	  one	  was	  
probed	  against	  ß-­‐actin	  (~45	  kDa).	  Membranes	  were	  blocked	  with	  5	  %	  BSA	  or	  
3	  %	  dry	  milk	  in	  50	  mM	  Tris,	  150	  mM	  NaCl	  supplemented	  with	  0.05	  %	  Tween	  
20	   (TBST)	   for	   ~1	   hour	   at	   room	   temperature	   (RT).	   After	   that,	   membranes	  
were	  incubated	  with	  primary	  antibodies	  and	  diluted	  in	  TBST	  as	  indicated	  in	  
Table	  1.	  After	  incubation	  overnight	  at	  4_ºC,	  membranes	  were	  washed	  twice	  
in	   TBST	   for	   5	   minutes	   at	   RT	   and	   gentle	   rocking.	   Then,	   membranes	   were	  
incubated	   with	   horseradish	   peroxidase	   (HRP)-­‐conjugated	   secondary	  
antibodies	  directed	  against	  each	  primary	  antibody	  diluted	  in	  TBST	  (Table	  1)	  
at	  RT	  for	  ~1	  hour.	  Membranes	  were	  washed	  twice	  with	  TBST	  for	  5	  min.	  The	  
antigen-­‐antibody	   complexes	   were	   then	   developed	   by	   chemiluminiscence	  
(West	  Pico	  34080)	  following	  the	  instructions	  of	  the	  manufacturer,	  visualized	  
by	   using	   the	   BioRad	   image	   analyzer	   (Chemi-­‐Doc	   MP	   Imaging	   system,	  
Hercules,	  CA)	  and	  digitized	  for	  densitometric	  analysis.	  	  
Densitometry	  
The	   bands	   developed	   by	   using	   anti-­‐NKCC1,	   -­‐NKCC2	   and	   ß-­‐actin	  
antibodies	   in	  Western	   blotting	  were	   digitally	   acquired	   by	   using	   Image	   Lab	  
Quantitative	   software	   (BioRad,	   Hercules,	   California)	   and	   adjusted	   to	   8-­‐bit	  
images	   in	   ImageJ	   (NIH)	  before	  densitometry	  analysis.	  The	  detailed	  protocol	  
for	   acquiring	   densitometry	   data	   by	   using	   ImageJ	   can	   be	   found	   at	  
lukemiller.org/index.php/2010/11/analyzing-­‐gels-­‐and-­‐western-­‐blots-­‐with-­‐
image-­‐j/.	   The	   optical	   density	   of	   the	   bands	   corresponding	   to	   NKCC1	   and	  
NKCC2	  were	  normalized	  to	  that	  of	  ß-­‐actin	  by	  dividing	  the	  intensity	  volume	  of	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each	   of	   them	   by	   the	   respective	   intensity	   volume	   of	   ß-­‐actin	   band.	   Once	   the	  
relative	   intensity	   (NKCC1	  or	  NKCC2/ß-­‐actin)	  of	  each	   lane	  was	  calculated,	   it	  
was	   further	   related	   to	   Control	   values	   i.e.,	   those	   obtained	   in	   the	   absence	   of	  
treatment	   or	   treated	  with	   vehicle	   alone.	   These	   values	  were	   used	   to	   plot	   a	  
curve	   of	   relative	   expression	   levels	   of	   NKCC1	   or	   NKCC2	   (y-­‐axis)	   vs.	  
bumetanide	  concentrations	  (x-­‐axis)	  (see	  Fig	  13B).	  
Total	  RNA	  extraction	  and	  reverse	  transcription	  (RT)	  coupled	  to	  PCR	  
Total	  RNA	   from	  MIN6	  ß-­‐cells,	  mouse	   islets	  or	   tissues	   in	  general	  was	  
obtained	  by	  using	  the	  GenJet	  RNA	  purification	  kit	  (Thermo	  Scientific	  K0731)	  
following	   the	  manufacturers'	   instructions.	   First-­‐strand	   cDNA	   synthesis	   and	  
PCR	  was	  performed	  as	  described	  in	  detail	  elsewhere	  (Alshahrani	  et	  al.	  2012).	  
Simultaneous	   screening	   of	   NKCC1a	   and	   NKCC1b	   transcripts	   in	   MIN6	   and	  
islets	   was	   done	   following	   the	   original	   strategy	   developed	   by	   Mao	   and	  
collaborators	   (Mao,	   et	   al.	   2012)	   and	   successfully	   applied	   to	   ß-­‐cells	  
(Alshahrani	   et	   al.	   2012)	   and	  COS7	   cells	   (Singh	   et	   al.	   2014).	  NKCC1,	  NKCC2	  
and	  control	  transcripts	  were	  amplified	  by	  using	  the	  primers	  sets	  indicated	  in	  
Table	   2.	   All	   primer	   sets	  were	  designed	  by	  using	  Geneious	  R7	   (Biomatters,	  
Auckland,	  NZ).	  The	  nucleotide	  sequence	  of	  RT-­‐PCR	  products	  was	  determined	  
to	  confirm	  molecular	  identity	  (Beckman	  Coulter	  Genomics,	  Beverly,	  MA).	  
Immunofluorescence	  Microscopy	  	  
Pancreas	  tissues	  were	  obtained	  from	  transcardially	  perfused	  mice	  of	  
the	  WT	  or	  NKCC2A-­‐KO	  genotypes	  and	  placed	   in	  4%	  p-­‐formaldehyde	  (PFA).	  
Perfusion	  was	  performed	  as	   follows:	  The	  mouse	  was	  anesthetized	  by	  using	  
Euthasol	   (Virbac	   302085-­‐020,	   390	   mg/ml)	   diluted	   to	   reach	   final	  
concentration	  of	  78	  mg/ml	  and	  then	   the	  necessary	  volume	   in	  µl	   injected	   to	  
reach	   a	   dose	   of	   150	   mg/kg.	   After	   the	   complete	   absence	   of	   mouse	   reflex	  
responses,	  abdominal	  and	  thoracic	  cavities	  were	  opened	  to	  expose	  the	  heart.	  
First,	   tissues	  were	  washed	  with	  PBS	  and	  a	  needle	   inserted	   into	   the	  apex	  of	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left	   ventricle	   and	   then	   the	   right	   ventricle	   was	   cut	   to	   allow	   the	   blood	   and	  
perfusion	  solutions	  to	  exit	  the	  circulation.	  Blood	  was	  drained	  by	  continuous	  
infusion	  of	  PBS	  by	  using	  a	  peristaltic	  pump	  (Masterflex	  77200-­‐62).	  When	  the	  
exiting	   fluid	   became	   clear,	   fixation	   process	   of	   tissues	   was	   performed	   by	  
perfusing	  4	  %	  PFA	  solution	  into	  the	  heart	  to	  allow	  tissue	  distribution.	  After	  
tissues	   color	   became	  white	   and	  muscle	   contraction	   stopped,	   perfusion	  was	  
considered	   completed.	   Then,	   perfused	   tissues	  were	   collected	   and	  placed	   in	  
labeled	   tubes	   containing	   4	   %	   PFA	   and	   kept	   overnight	   at	   4_°C.	   Next	   day,	  
tissues	  were	  placed	  in	  fresh	  20	  %	  sucrose/4	  %	  PFA	  for	  paraffin	  embedding.	  
Paraffinized	   tissues	  were	   sent	   to	   AML	   laboratories,	   Inc	   (Baltimore,	  MD)	   to	  
generate	   5	   µm	   slides	   sections.	   After	   slide	   sections	   were	   received,	   the	  
following	  steps	  were	  performed	  	  
Tissues	  sections	  on	  slides	  were	   fixed	  by	  using	  4	  %	  PFA	  overnight	  at	  
4_°C	   and	   deparaffinized	   with	   xylene	   for	   5	   min	   twice.	   Then,	   slides	   were	  
washed	  twice	  with	  95%	  ethanol	  and	  successively	  with	  80	  %,	  70	  %,	  and	  50	  %	  
ethanol	   for	   5	   minutes	   each.	   After	   that,	   sections	   were	   rinsed	   with	   distilled	  
water	  before	  rinsed	  again	  with	  PBS	  for	  10	  min.	  Slides	  then	  were	  transferred	  
to	  water	  bath	  in	  a	  staining	  dish	  containing	  sodium	  citrate	  buffer	  (10	  mM)	  at	  
95-­‐100_ºC	   for	   30	  min.	   Slides	  were	   incubated	   at	   room	   temperature	   30	  min	  
before	  washing	  with	  PBS-­‐0.1	  %	  triton.	  Sections	  then	  were	  blocked	  with	  goat	  
serum	  diluted	  in	  PBS	  (1:10)	  30	  min	  at	  room	  temperature	  and	  then	  incubated	  
with	  primary	  antibodies	  as	  indicated	  in	  Table	  1	  diluted	  in	  PBS-­‐0.1	  %	  Triton	  
overnight	  at	  4ºC.	  Next	  day,	  sections	  were	  washed	  three	  times	  with	  PBS/0.1	  
%	   Triton	   for	   10	   minutes	   each	   and	   then	   incubated	   with	   appropriate	  
secondary	  antibodies	  (Table	  1)	  for	  2	  hours	  at	  room	  temperature	  in	  the	  dark.	  
When	   appropriate,	   4',6-­‐diamidino-­‐2-­‐phenylindole	   (DAPI)-­‐containing	  
mounting	  media	  was	  used	  in	  the	  sections	  to	  counterstain	  cell	  nuclei.	  Digital	  
images	   were	   taken	   by	   using	   the	   BX51	   system	   fluorescence	   microscope	  
(Olympus	  Corp,	  Tokio,	   Japan)	  connected	   to	  a	  Spot	  5.1	  digital	  camera	  (SPOT	  
Imaging	  Solutions,	  Diagnostic	  Instruments,	  Inc.	  Sterling	  Heights,	  MI)	  coupled	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to	   MetaVue	   software	   (Molecular	   Devices,	   Sunnyvale,	   CA).	   Slides	   of	   tissues	  
from	  mice	   lacking	   NKCC1	  were	   also	   used	   for	   control	   purposes.	   NKCC1-­‐KO	  
mice	  were	  generated	  by	  Dr.	  Gary	  Shull,	  University	  of	  Cincinnati	  (Flagella,	  et	  
al.	  1999)	  and	  generously	  provided	  by	  Dr.	  Alvarez-­‐Leefmans	  (WSU-­‐BSoM).	  
Insulin	  Secretion	  
The	  supernatant	  of	  sub-­‐confluent	  MIN6	  ß-­‐cells	  growing	  under	  normal	  
or	  glucose/drug-­‐stimulated	  conditions	  was	  used	  to	  determine	  the	  amount	  of	  
insulin	   released	   to	   the	   media,	   a	   simple	   criterion	   of	   insulin	   secretion.	   The	  
assay	  was	   designed	   as	   follows:	  MIN6	   ß-­‐cells	  were	   plated	   in	   12-­‐well	   plates	  
(Falcon	   353043)	   in	   complete	   DMEM	   media	   (Hyclone,	   Cat#	   sh30243.01)	  
supplemented	   with	   sodium	   pyruvate	   and	   450	   mg/dl	   glucose,	   10	   %	   FBS,	  
glutamine	   and	   2	   µl	   of	   2-­‐mercaptoethanol.	   On	   day	   one,	   cells	   were	   washed	  
twice	   with	   sterile	   glucose-­‐free	   Krebs-­‐Ringer	   Bicarbonate/HEPES	   buffer	  
(KRBH)	   containing	   per	   100	  ml	   of	   deionized	  water	   the	   following:	   2.7	  ml	   of	  
NaCl	  5M	   (Sigma	  S5150),	  4.8	  ml	  KCl	  75	  mM	  (Sigma	  P9327),	  562	  μl	  NaHCO3	  
0.89	  M	  (Sigma	  S8761),	  100	  μl	  NaH2PO4	  0.5	  M	  (Sigma	  94046),	  50	  μl	  MgCl2	  1	  M	  
(Affimetrix/USB	  #78641),	  150	  μl	  CaCl2	  1	  M	  (Sigma	  21114),	  1	  ml	  HEPES	  1	  M	  
(Sigma	  H0887)	   and	   100	  mg	  BSA	   (Sigma	  A7906).	   After	  washing,	   cells	  were	  
incubated	  for	  30	  min	  with	  KRBH	  (1	  ml	  per	  well)	  freshly	  supplemented	  with	  
5.5	  mM	   glucose	   (22	   µl	   of	   glucose	   stock	   250	  mM).	   Cells	  were	   then	  washed	  
twice	  with	  glucose-­‐free	  KRBH.	  After	  this	  washing,	  cells	  were	  incubated	  for	  2h	  
in	   fresh	   KRBH	   supplemented	  with	   several	   concentrations	   of	   glucose	   (non-­‐
insulinotropic:	  1-­‐5.5	  mM	  and	  insulinotropic:	  5.5-­‐20	  mM)	  to	  generate	  a	  curve	  
of	  insulin	  secretion	  as	  that	  shown	  in	  Figure	  16A	  in	  the	  Results	  section.	  To	  test	  
the	  effects	  of	  bumetanide	  (BTD,	  Sigma	  B3023)	  on	  insulin	  secretion,	  MIN6	  ß-­‐
cells	   were	   incubated	   with	   KRBH	   plus	   the	   diuretic	   at	   the	   concentrations	  
indicated	   in	   relevant	   each	   sections.	   Then,	   glucose	   was	   added	   as	   explained	  
above.	   After	   2	   hs,	   800	   µl	   of	   supernatants	   were	   collected,	   fractionated	   and	  
stored	  at	  −20_ºC	  overnight.	  The	  next	  day,	  supernatants	  were	  centrifuged	  at	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12,000	   rpm	   for	   10	   min	   (Sorvall	   Legend	   Micro	   21R	   centrifuge,	   Thermo	  
Scientific)	  to	  remove	  any	  cell	  debris.	  The	  supernatants	  were	  diluted	  1:20	  by	  
adding	  appropriate	  amounts	  of	  deionized	  water	  and	  used	  for	   insulin	  assays	  
(see	   bellow).	   To	   estimate	   the	   proportion	   of	   insulin	   secreted	   relative	   to	   the	  
total	  amount	  of	  insulin	  in	  cells,	  the	  total	  insulin	  content	  of	  MIN6	  ß-­‐cells	  was	  
estimated	  after	  extraction	  of	  the	  hormone	  in	  acidified	  ethanol	  (75	  %	  ethanol,	  
1.5	   %	   concentrated	   HCl).	   Briefly,	   after	   supernatants	   were	   collected,	   cells	  
were	   extracted	   by	   adding	   1	   ml	   of	   acidified	   ethanol	   per	   well	   overnight	   at	  
−20_ºC.	   Next	   day,	   800µl	   of	   acidified	   ethanol	   extracts	   were	   collected	   and	  
centrifuged	  at	  12,000	  rpm	  for	  10	  min	  as	  above.	  The	  cellular	  extracts	  obtained	  
were	   diluted	   1:250	   with	   de-­‐ionized	   water	   and	   assayed	   for	   insulin	   content	  
(see	  bellow)	   i.e.,	   the	   total	   amount	   of	   insulin	   contained	   in	   cultured	  MIN6	   ß-­‐
cells.	  	  
	  To	  test	  the	  long-­‐term	  effect	  of	  BTD	  on	  insulin	  secretion,	  MIN6	  ß-­‐cells	  
were	  pre-­‐incubated	  with	  several	  concentrations	  of	  the	  diuretic	  for	  16	  hours	  
before	   insulin	   secretion	   assays	   were	   performed.	   Insulin	   secretion	   is	  
expressed	   either	   as	   percentage	   change	   relative	   to	   basal	   values	   i.e.,	   those	  
obtained	   with	   non-­‐insulinotropic	   glucose	   concentrations	   (<5.5	   mM)	   or	  
relative	  to	  total	  insulin	  content	  calculated	  as	  follows:	  insulin	  in	  supernatant	  /	  
insulin	  in	  supernatants	  +	  insulin	  content	  =	  fraction	  of	  insulin	  secreted.	  
Insulin	   concentration	   in	   samples	   (plasma,	   supernatants	   or	   extracts)	  
was	   determined	   by	   using	   a	  mouse	   ultrasensitive	   "sandwich-­‐type"	   enzyme-­‐
linked	   immunoabsorbent	   assay	   (ELISA,	   APLCO	   80-­‐INSMSU-­‐E01)	   in	   the	   96	  
microplate	   format	   and	   following	   the	   instructions	   of	   the	   manufacturer.	  
Briefly,	  the	  assay	  consisted	  in	  the	  following:	  5	  µl	  of	  insulin	  Standards	  having	  
0,	  0.188,	  0.5,	  1.25,	  3.75,	  and	  6.9	  	  ng/ml	  of	  mouse	  insulin,	  two	  plasma	  controls	  
containing	   low	   or	   high	   insulin	   concentration	   (see	   inset	   Figure	   8),	   plasma	  
obtained	  from	  mice	  or	  samples	  from	  MIN6	  ß-­‐cells	  added	  in	  duplicate	  to	  wells	  
containing	   a	   monoclonal	   antibody	   against	   mouse	   insulin	   attached	   to	   the	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bottom	   of	   the	   wells.	   Then,	   75	   µl	   of	   HRP-­‐conjugated	   antibodies	   directed	  
against	  insulin	  (a	  different	  epitope	  relative	  to	  the	  first	  antibody)	  were	  added	  
to	   the	  wells	  and	   incubated	   for	  2	  hours	  at	   room	  temperature	  on	  a	   rocker	  at	  
700-­‐900	  rpm.	  Wells	  were	  then	  carefully	  washed	  six	  times	  by	  using	  300	  µl	  of	  
Wash	   Buffer	   supplied	   in	   the	   kit.	   Then,	   100	   µl	   per	   well	   of	   3,3',5,5'-­‐
tetramethylbenzidine	   (TMB)	   substrate	   to	   detect	   HRP	   activity	   were	   added	  
and	   allowed	   additional	   30	   min	   of	   incubation	   at	   room	   temperature	   on	   the	  
rocker	  (700-­‐900	  rpm).	  To	  develop	  the	  color	  of	  the	  reaction,	  100	  µl	  per	  well	  of	  
a	   Stop	   solution	   were	   added	   and	   the	   optical	   density	   or	   absorbance	  
determined	   at	   450	   nm	   in	   a	   multi-­‐well	   plate	   reader	   (Packard	   Bioscience	  
Company	  425228).	  The	  relationship	  between	  absorbance	  and	  insulin	  content	  
in	  this	  assay	  follows	  a	  linear	  function	  over	  the	  range	  of	  insulin	  concentrations	  
shown	  in	  Figure	  8.	  
Determination	  of	  cellular	  Cl–	  uptake	  
The	  total	  intracellular	  content	  of	  Cl–	  ions	  in	  cultured	  cells	  or	  islets	  was	  
determined	   by	   potentiometry	   by	   using	   calibrated	   Cl–-­‐selective	   electrodes	  
(Thermo	   Sci-­‐Orion)	   following	   essentially	   the	   methods	   described	   by	  
Northrop,	  Sanderson	  and	  Weinstein	  &	   Jennings	  (Northrop	  1948;	  Sanderson	  
1952;	   Weinstein	   and	   Jennings	   1959)	   and	   the	   initial	   supervision	   of	   Dr.	  
Kenneth	   Gagnon	   (Anatomy	   and	   Cell	   Biology,	   University	   of	   Saskatchewan,	  
Canada).	  The	  relationship	  between	  the	  concentration	  of	  Cl–	   ions	   in	  moles/L	  
and	   the	   response	   of	   the	   Cl–	   electrode	   in	   mV	   at	   25_ºC	   is	   described	   by	   the	  
Nernst	  equation:	  
	   	   	   E	  (mV)	  =	  k	  −	  59.2	  x	  log[Cl–]	  	  
Therefore,	   the	   electrode	   response	   to	   calibrated	   and	   accurately	  
prepared	  NaCl	   solutions	   of	   concentrations	   ranging	   from	  0.0001	  mM	   (pCl	   =	  
−4)	  to	  500	  mM	  (pCl	  =	  2.7)	  were	  converted	  to	  [Cl–]	  by	  using	  standard	  curves	  
plotting	  E	  vs.	  pCl	  (Figure	  9).	  To	  determine	  the	  accuracy	  of	  the	  Cl–	  electrode,	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Figure 8. Insulin standard curve. Non-linear regression analysis 
performed on the relationship between optical density or absorbance  
measured at 450 nm and increasing concentrations of mouse insulin (0 - 6.9 
ng/ml) as determined by ELISA. The standard curve produced is used to 
determine the concentration of insulin in cell culture supernatants, cell 
extracts or plasma samples. Inset: Internal controls for ELISA using 10 
different plasma samples with low or high levels of  insulin (red and blue 
dots, respectively).
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preliminary	  experiments	  were	  performed	  at	  high	  and	  constant	  ionic	  strength	  
by	   supplementing	   samples	   and	   standards	  with	  NaNO3	   1	  M.	   There	  were	   no	  
differences	   in	   the	  electrode	  responses	   in	   the	  presence	  or	  absence	  of	  NaNO3	  
indicating	  that	  the	  ionic	  strength	  of	  the	  samples	  were	  low	  enough	  to	  impact	  
the	  electrode	  responses	  and	  therefore,	  this	  step	  was	  omitted.	  
To	  determine	  Cl–	  content	  in	  cells,	  COS7	  or	  MIN6	  were	  seeded	  onto	  6-­‐
well	   plastic	   plates	   (Thermo	   Scientific	   #130184)	   and	   grown	   until	   ~80	   %	  
confluence	  was	   reached.	   In	   the	   case	   of	   islets,	   they	  were	   plated	   onto	   6-­‐well	  
plates	   for	   two	  days	   to	   allow	   attachment.	   Cells	   or	   islets	  were	   then	   carefully	  
washed	   and	   depleted	   of	   endogenous	   Cl–	   by	   pre-­‐incubating	   them	   in	   an	  
isotonic	  solution	   lacking	  Cl–	   ions	  and	  the	  composition	   indicated	   in	  Table	   3.	  
The	   osmolarity	   of	   the	   solutions,	   as	   determined	   by	   using	   an	   osmometer	  
(Advanced	   Instruments,	   Inc.	   3300),	   averaged	   310	  mOsm/kg.	   After	   the	   pre-­‐
incubation	   period,	   Cl–-­‐free	   ISO	   was	   aspirated	   and	   replaced	   by	   an	   isotonic	  
solution	   containing	  physiological	   concentrations	  of	  Cl–	   (ISO,	  Table	   3).	  Cells	  
or	   islets	   were	   incubated	   at	   room	   temperature	   in	   ISO	   solution	   for	   variable	  
periods	   of	   time	   in	   order	   to	   obtain	   either	   a	   mono-­‐exponential,	   first-­‐order	  
kinetic	   curve	   of	   Cl–	   uptake	   or	   end-­‐point	   uptake	   of	   the	   anion.	   For	   kinetic	  
analysis,	  Cl–	  uptake	  into	  cells	  was	  terminated	  at	  0,	  5,	  10,	  30	  or	  60	  min	  after	  
incubation	   in	   ISO	   media	   by	   placing	   cells	   on	   ice,	   aspirating	   the	   media	   and	  
immediately	  applying	  three	  washes	  of	  ice-­‐cold	  Cl–-­‐free	  ISO	  solution	  at	  those	  
time	   points.	   The	   ionic	   content	   of	   washed	   cells	   was	   then	   released	   by	  
incubating	   cells	   in	   0.25	   N	   NaOH	   at	   room	   temperature	   for	   30	   min.	   After	  
neutralization	   with	   glacial	   acetic	   acid,	   aliquots	   were	   accurately	   taken	   for	  
protein	  determination	  and	   for	   the	  potentiometric	  determination	  of	  Cl–	   ions	  
present	  in	  the	  samples.	  	  Net	  Cl–	  uptake	  in	  cells	  was	  calculated	  and	  expressed	  
as	  nmol	   of	   Cl–	   per	  µg	  of	   total	   protein	   content.	  BTD-­‐sensitive	  Cl–	   uptake	   i.e.,	  
NKCC-­‐mediated	  was	  defined	  as	  the	  difference	  between	  Cl–	  accumulated	  in	  5	  
minutes	   and	   that	   obtained	   in	   the	   presence	   of	   BTD.	   To	   test	   the	   long-­‐term	  
effects	  of	  BTD	  on	  Cl–	  accumulation,	  cells	  were	  incubated	  with	  the	  diuretic	  for	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Figure 9. Calibration curve of the ion-selective electrode. The response of 
the ion-selective electrode in mV to increasing concentrations of Cl ions 
ranging from 0.00001 to 500 mM was plotted following the relationship 
determined by the Nernst equation. The electrode responses for each pCl 
represents the mean ± range (n=12). The grey zone represents the minimum 
values of Cl concentrations detected by the electrode. The effective linear 
range of Cl concentration in which the electrode gives a response in mV with 
a slope of ~56 mV occurs from 0.1 µM to 500 mM.
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Table 3
Stock Solutions & salts ISO Cl-free Final Concentration
NaCl 5M 13 ml 0 130 mM
KCl 75mM 33.3 ml 0 5 mM
CaCl2 1M 1 ml 0 2 mM
Na2HPO4 0.5M 0.83 ml 0.83 ml 0.83 mM
MgSO4 1M 0.5 ml 0.5 ml 1 mM
HEPES 1M 10 ml 10 ml 20 mM
Na-gluconate 0 14.18 g 130 mM
K-gluconate 0 0.5865 g 5 mM
Ca-gluconate 0 0.4304 g 2 mM
Mannose 2.5g 2.5g 10 mM
pH 7.4, Water to 500 ml 500 ml
Osmolarity ~300 mOsm/k ~300 mOsm/k
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16	  hours	  and	  then	  depleted	  of	  endogenous	  Cl–	  by	  incubating	  them	  1	  hour	  in	  
Cl–-­‐free	   ISO	   containing	   BTD	   followed	   by	   5	   min	   ISO	   incubation,	   also	   in	   the	  
presence	  of	  BTD.	  For	  end-­‐point	  determination	  of	  Cl–	  uptake,	  islets	  depleted	  of	  
the	  anion	  were	  incubated	  30	  minutes	  in	  ISO	  with	  or	  without	  BTD.	  
	  
Statistical	  analysis	  
Data	   are	   expressed	   as	   mean	   ±	   SEM.	   One–way	   analysis	   of	   variance	  
(ANOVA)	   was	   used	   to	   compare	   between	   multiple	   groups.	   Student’s	   two-­‐
tailed	   t-­‐test	   was	   used	   for	   paired	   comparisons.	   To	   calculate	   kinetic	  
parameters	  of	  chloride	  data,	  one-­‐phase	  decay	  best	  fitting	  analysis	  was	  used.	  









NKCC1	  and	  NKCC2	  are	  expressed	  in	  MIN6	  ß-­‐cells	  and	  mice	  islets	  
To	   determine	   and	   identify	   expression	   of	   NKCC1	   and	   NKCC2	   in	   our	  
mouse	  ß-­‐cell	  model	  MIN6,	  we	  used	  RT-­‐PCR	  and	  the	  sets	  of	  primers	  shown	  in	  
Table	  2.	  A	  graphic	  representation	  of	  NKCC1	  and	  NKCC2	  primers	  is	  depicted	  
in	   Figure	   10A.	   Note	   that	   some	   of	   these	   primer	   sets	   are	   designed	   to	   co-­‐
amplify	  more	  than	  one	  splice	  variant	  of	  NKCC1	  or	  NKCC2	  in	  a	  single	  reaction.	  
For	  instance,	  primer	  set	  NKCC1-­‐599a/551b	  encompasses	  a	  region	  of	  NKCC1	  
transcripts	   involving	   exon	   21,	   a	   48	   bp	   sequence	   cassette	   eliminated	   in	  
NKCC1b	   (see	   Fig	   6A).	   Therefore,	   co-­‐amplification	   of	   NKCC1	   transcript	  
fragments	  of	  599	  bp	  and	  551	  bp	  indicates	  expression	  of	  NKCC1a	  and	  NKCC1b	  
transcripts,	   respectively.	   In	   the	   case	   of	   the	   primer	   set	   NKCC2-­‐700,	   no	  
difference	  in	  RT-­‐PCR	  product	  length	  is	  expected	  because	  alternative	  exons	  A,	  
B	  or	  F	  are	  all	  of	  96	  bp	  (see	  Fig	  6B)	  (Di	  Fulvio	  and	  Alvarez-­‐Leefmans	  2009).	  
Therefore,	   NKCC2-­‐700	   is	   predicted	   to	   co-­‐amplify	   NKCC2A,	   NKCC2B	   and	  
NKCC2F	   as	   a	   single	   amplicon	   of	   700	   bp,	  which	  may	   be	   identified	   by	   direct	  
sequencing.	  
As	   shown	   in	   Figure	   10B,	   NKCC1a	   transcripts	   of	   expected	   sizes	   are	  
found	  in	  MIN6	  ß-­‐cells.	  In	  addition,	  and	  contrary	  to	  rat	  ß-­‐cell	  lines	  (Alshahrani	  
et	  al.	  2012),	  faint	  bands	  of	  551	  bp	  and	  453	  bp	  corresponding	  to	  NKCC1b	  were	  
also	   co-­‐amplified	   when	   using	   NKCC1-­‐599a/551b	   or	   NKCC1-­‐501a/453b	  
primer	   sets	   (see	   red	  arrows	   in	   Fig	   10B)	   suggesting	   that	   both,	   NKCC1a	   and	  
NKCC1b	  mRNAs	   are	   co-­‐expressed	   in	  MIN6	   ß-­‐cells.	  Figure	   10C	   also	   shows	  
that	   NKCC2	   is	   expressed	   at	   the	   mRNA	   level	   in	   MIN6	   ß-­‐cells,	   extending	  
previous	   results	   (Alshahrani	   et	   al.	   2012).	   To	   determine	   the	   molecular	  














































































G TCTGGG CG TCA TCA TCA TTGG CCTGAG CG TAG TTG TGA CAA CA CTCA CAGG TA TTTCTA TG TCGG CTA TTTG CA CAAA CGGAG TGG TG CGAGGAGG T
G TCTGGG CG TCA TCA TCA TTGG CCTGAG CG TAG TTG TGA CAA CA CTCA CAGG TA TTTCTA TG TCGG CTA TTTG CA CAAA CGGAG TGG TG CGAGGAGG T
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Exon F (exon 6)
D
Figure 10. Molecular and cellular expression of NKCC1 and NKCC2 in MIN6 ß-cells. A. 
Schematic representation of NKCC1 (top) and NKCC2 (bottom) transcripts, their exons (grey arrowed 
boxes), coding regions (yellow arrowed boxes) and the relative positions of the primer sets used. 
They are named according to the transcript amplified and followed by three numbers indicating the 
predicted size in base pairs (bp) of the RT-PCR products. B-C. Representative RT-PCR experiments 
performed showing bands of predicted sizes for NKCC1 (B) and NKCC2 (C). D. Sequence identity of 
the NKCC2-700 amplicon (red asterisk in C). Shown is the partial nucleotide sequence aligned 
against the sixth exon of NKCC2 gene (exon F). E-F. Immunofluoresence analysis of MIN6 ß-cells 
growing in glass coverslips and probed against NKCC1 (E) or NKCC2 (F) by using the  primary and 
secondary antibodies shown in Table 1.   
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identity,	   the	  NKCC2	  amplicon	  of	  700	  bp	  obtained	  in	  MIN6	  ß-­‐cells	  (indicated	  
with	   a	   red	   asterisk	   in	   Fig	   10C)	   was	   purified	   and	   sequenced.	   As	   shown	   in	  
Figure	   10D,	   the	  partial	  nucleotide	  sequence	  of	  NKCC2	   transcripts	  detected	  
in	  MIN6	   ß-­‐cells	   correspond	   to	   the	   F	   (exon	   6)	   variant.	   At	   the	   cellular	   level,	  
both	   immunoreactive	  NKCC1	   and	  NKCC2	   proteins	   are	   detected	   in	   cultured	  
MIN6	   cells.	   Representative	   images	   of	   these	   results	   are	   shown	   in	   Figures	  
10E-­‐F.	  	  	  	  
To	  further	  extend	  these	  results	  to	  the	  mouse	  islet,	  NKCC1	  and	  NKCC2	  
transcripts	  were	   amplified	   by	   RT-­‐PCR	   using	   some	   of	   the	   same	   primer	   sets	  
used	  to	  detect	  NKCC1	  and	  NKCC2	  in	  MIN6	  ß-­‐cells	  (Figs	  10A-­‐B).	  As	  shown	  in	  
Figure	  11A,	  NKCC1a	  and	  faint	  NKCC1b	  (red	  arrows)	  mRNAs	  are	  detected	  in	  
total	   RNA	   extracts	   from	   purified	   mice	   WT	   islets.	   In	   addition,	   Figure	   11B	  
shows	   that	   NKCC2	   is	   also	   detected	   at	   the	   transcript	   level	   in	   mice	   islets	  
confirming	  previous	  results	  (Alshahrani	  et	  al.	  2012;	  Alshahrani	  and	  Di	  Fulvio	  
2012).	   To	   determine	   the	   molecular	   identity	   of	   NKCC2	   expressed	   in	   those	  
islets,	   the	   RT-­‐PCR	   fragment	   obtained	   with	   NKCC2-­‐700	   (red	   asterisk	   in	   Fig	  
11B)	   was	   purified	   and	   sequenced.	   As	   shown	   in	   Figure	   11C,	   the	   partial	  
nucleotide	   sequence	   of	   NKCC2	   transcripts	   detected	   in	   mouse	   islets	  
corresponds	  to	  the	  F	  (exon	  6)	  variant.	  
To	  correlate	  NKCC	  transcripts	  with	  their	  products,	  protein	  expression	  
and	  localization	  of	  NKCC1	  were	  determined	  at	  the	  cellular	  level	  in	  mice	  islets	  
by	  co-­‐immunolabeling	  NKCC1	  or	  NKCC2	  with	  insulin,	  the	  latter	  to	  identify	  ß-­‐
cells	   of	   the	   islets.	   To	   this	   end,	   mice	   pancreas	   slides	   were	   probed	   against	  
NKCC1	   by	   using	   validated	   primary	   chicken	   antibodies	   directed	   against	  
human	  NKCC1	  (Singh	  et	  al.	  2014)	  and	  one	  of	   the	  most	  commonly	  used	  and	  
thoroughly	  characterized	  antibodies	  against	  insulin	  (see	  Table	  1).	  As	  shown	  
in	  Figure	  11D,	  NKCC1	  is	  expressed	  in	  the	  islet	  of	  WT	  but	  not	   in	  NKCC1-­‐KO	  
mice,	   as	   expected	   (Flagella	   et	   al.	   1999).	   Notably,	   NKCC1	   locates	   in	   insulin-­‐
positive	  ß	  cells	  in	  mice	  islets.	  Following	  a	  similar	  strategy,	  Figure	  11E	  shows	  





































G L G V I I I G L S V V V T T L T G I S M S A I C T N G V V R G G

























Figure 11. Molecular and cellular 
expression of NKCC1 and 
NKCC2 in mouse islets. A. 
NKCC1a and NKCC1b transcript 
expression in WT islets was 
analyzed by RT-PCR using the 
primer sets NKCC1-515 (first lane), 
501a/453b (second lane) and 
599a/551b (third lane). B. NKCC2 
mRNA expression in WT islets as 
determined by using RT-PCR and 
the NKCC2-700 primer set. As 
positive control of RT-PCRs 
transcripts of GAPDH were 
amplified (555 bp). As negative 
control, water was used instead of 
total RNA. C. Partial sequence 
chromatogram obtained from a 
representative DNA sequencing 
reaction using purified NKCC2-700 
amplicons (red asterisk). Note that 
the DNA sequence obtained is 
100% identical to that of exon 6 
(exon F) of NKCC2 (Slc12a1 v2, 
NM_001079690). Experiments 
performed by Shams Kursan. D-E. 
Representative immunolocalization 
experiments for NKCC1 (D) and 
NKCC2 (E) and insulin using 
pancreas slides from mice of the 
indicated genotypes. The 
antibodies used in these 
experiments are indicated in Table 
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immunoreactive	  NKCC2	  locating	  in	  insulin-­‐positive	  ß-­‐cells	  in	  WT	  islets,	  as	  we	  
have	   previously	   demonstrated	   (Alshahrani	   and	   Di	   Fulvio	   2012).	   Further,	  
immunoreactive	  NKCC2	  is	  also	  detected	  in	  ß-­‐cells	  of	  islets	  of	  pancreas	  from	  
NKCC2A-­‐KO	  mice	  supporting	  the	  notion	  that,	  contrary	  to	  rat	  ß-­‐cells,	  NKCC2	  
splice	  variant	  F	  is	  expressed	  in	  mice	  islets.	  	  
MIN6	  ß-­‐cells	  and	  islets	  accumulate	  Cl–	  ions	  
The	   presence	   of	   NKCC1	   and	   NKCC2	   in	   MIN6	   predicts	   active	   BTD-­‐
sensitive	   accumulation	   of	   Cl–	   ions	   by	   these	   cells.	   Therefore,	   to	   determine	  
functional	   NKCC	   expression,	   MIN6	   ß-­‐cells	   were	   depleted	   of	   endogenous	   Cl–	   
and	  subsequently	  allowed	  to	  accumulate	  this	  anion	  as	  a	  function	  of	  time.	  As	  
shown	  in	  Figure	   12A,	  Cl–-­‐depleted	  MIN6	  ß-­‐cells	  accumulates	  Cl–	   in	   isotonic	   
media	   containing	   physiological	   concentrations	   of	   Cl–	   (ISO)	   following	   a	   time	  
curve	   typical	   of	   first-­‐order	   kinetics	   with	   a	   rate	   constant	   k	   =	   0.124	   min-­‐1,	   a	   
maximal	    halfr life	    T1/2	    =	    5.6	    min	    and	    a	    plateau	    P	    =	    3.96	    nmol/µg	   
protein.	   However,	   such	   accumulation	   kinetics	   is	   reduced	   in	   the	   
continuous	  presence	  of	  10	  µM	  BTD	  (k	  =	  0.111	  min-­‐1,	  T1/2	  =	  6.2	  min	  and	  P	  =	  
2.58)	  suggesting	  that	  MIN6	  ß-­‐cells	  accumulate	  Cl–	  in	  a	  BTD-­‐sensitive	  manner	  
a	   finding	   consistent	   with	   the	   notion	   that	   these	   cells	   express	   functional	   
NKCCs.	  
To	  add	  support	  to	  this	  conclusion,	  dose-­‐response	  inhibition	  curves	  of	  
BTD-­‐sensitive	   Cl–	   uptake	   (i.e.,	   the	   fraction	   of	   total	   Cl–	   accumulation	   that	   is	  
sensitive	  to	  BTD.	  In	  other	  words,	  NKCC-­‐mediated)	  as	  a	  function	  of	  increasing	  
concentrations	   of	   BTD	   were	   performed	   to	   determine	   the	   half-­‐maximal	  
inhibitory	  concentration	  (IC50)	  of	  the	  diuretic	  on	  NKCC	  function.	  As	  shown	  in	  
Figure	   12B,	   the	   BTD-­‐sensitive	   component	   of	   Cl–	   accumulation	   in	  MIN6	   ß-­‐
cells	  follows	  a	  typical	  inhibitory	  dose-­‐response	  curve	  with	  an	  estimated	  BTD	  
IC50	  of	  ~7-­‐9	  µM.	  	  	  	  
To	   extend	   these	   results	   to	  mice	   islets,	   Cl–	   uptake	   experiments	  were	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Figure 12. Kinetics of Cl uptake. A. Cl- uptake into MIN6 ß-cells depleted of intracellular Cl- under
control (red dots) or in the presence of the indicated concentration of BTD (blue dots). Cl- uptake
reaches equilibrium after ~10 minutes at room temperature and a final physiological Cl- 
concentration of ~140 mM. Results are expressed as mean ± SEM (n>10). The initial uptake rate 
is approximately linear during the first 5-10 minutes of the reaction. Thereafter, a mono-exponential 
decay in the uptake rate can be observed. B. Dose-response curve of Cl- uptake in Cl-depleted
MIN6 ß-cells determined 5 minutes after readmission of physiological Cl- in the presence of the
indicated concentrations of BTD. Results are expressed as the mean ± SEM (n>5). C. Maximal Cl-  
uptake into Cl-depleted NKCC2A islets. Results are expressed as the mean ± SEM (n=3).
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performed	   in	   cultured	   islets	   obtained	   from	   WT	   and	   NKCC2A-­‐KO	   mice	  
expressing	  NKCC2F	  and	  NKCC1	  (Figs	  12D-­‐E).	  To	  that	  end,	  islets	  were	  initially	  
depleted	   of	   endogenous	   Cl–	   and	   subsequently	   exposed	   to	   physiological	   Cl–	  
concentrations	  for	  an	  hour	  in	  order	  to	  determine	  the	  maximal	  content	  of	  Cl–	  
accumulated	  in	  the	  presence	  or	  absence	  of	  10	  µM	  BTD.	  As	  shown	  in	  Figure	  
12C,	  the	  maximal	  uptake	  of	  Cl–	  ions	  in	  mice	  islets	  of	  both	  genotypes	  exhibited	  
a	  BTD-­‐sensitive	  component	  corresponding	  fairly	  to	  40	  %	  of	  the	  total	  uptake	  
of	   the	  anion.	  These	   results,	  when	   taken	   together	   indicate	   that	  MIN6	  ß-­‐cells	  
and	  mice	  islets	  of	  both	  genotypes	  express	  functional	  NKCCs.	  
Down-­‐regulation	  of	  NKCC1	  increases	  NKCC2	  expression	  
The	  findings	  that	  NKCC1-­‐KO	  islets	  respond	  to	  glucose	  (Alshahrani	  and	  
Di	  Fulvio	  2012),	  and	  that	  mice	  islets	  express	  NKCC2	  prompted	  the	  question	  
as	  to	  what	  extent	  NKCC2	  might	  participate	  in	  long-­‐term	  regulation	  of	  Cl–	  in	  ß-­‐
cells	   co-­‐expressing	   both	   transporters.	   Therefore,	   to	   gain	   insights	   into	   the	  
potential	   long-­‐term	   effects	   of	   NKCC	   inhibition	   on	   either	   NKCC1	   or	   NKCC2	  
expression,	  MIN6	  ß-­‐cells	  were	  treated	  for	  16	  hours	  with	  1,	  5,	  10	  and	  50	  µM	  
BTD	   and	   NKCC	   protein	   expression	   levels	   determined	   by	   immunoblot	  
analysis.	   As	   shown	   in	   Figure	   13A,	   BTD	   progressively	   reduces	   NKCC1	  
expression	  in	  MIN6	  ß-­‐cells	  until	  reaching	  a	  maximum	  inhibitory	  effect	  at	  10-­‐
50	   µM,	   a	   phenomenon	   that	   closely	   paralleled	   increased	   NKCC2	   protein	  
expression	   levels.	   Indeed,	   densitometric	   analysis	   of	   at	   least	   three	  
independent	  Western	  blotting	  experiments	  shows	  the	  relationship	  between	  
the	  expression	  levels	  of	  NKCC1	  and	  NKCC2	  in	  MIN6	  ß-­‐cells	  (Figure	  13B).	  
To	   ascertain	   if	   increased	   levels	   of	   NKCC2	   expression	   occurs	   in	  
response	   to	   decreased	  NKCC1	   in	   a	   general	   rather	   than	   specific	   setting,	  we	  
first	   determined	   whether	   BTD	   impacted	   NKCC1	   expression	   in	   COS7,	   a	  
fibroblast-­‐like	   cell	   line	   wherein	   NKCC1	   expression	   has	   been	   thoroughly	  
characterized	   and	   validated	   (Singh	   et	   al.	   2014)	   and	   in	  which	   low	   levels	   of	  
NKCC2	   can	   be	   detected.	   As	   shown	   in	   Figure	   13C,	   incremental	   BTD	  




























































































Figure 13. Impact of BTD or NKCC1 depletion on NKCC expression. A. Representative 
immunoblot analysis of protein extracts obtained from MIN6 ß-cells (Control and treated with 
the indicated concentrations of BTD 16 hours) and probed against NKCC1 or NKCC2 by 
using NKCC1 or NKCC2 antibodies respectively. B. Densitometric analysis of at least three 
different immunoblots as the one shown in A. C. Representative immunoblot analysis of 
protein extracts obtained from COS7 cells treated with the indicated  concentrations BTD 16 
hours. D-E. Representative Western blots of COS7 cells and COS7 cells lacking NKCC1 
(shNKCC1) (D) or COS7 Control and COS7 depleted of endogenous NKCC2 (shNKCC2) (E) 
probed against NKCC1 and NKCC2 (experiments performed by Mohamed Almiahuob). F. 
Representative immunofluorescence experiments performed on COS7 cells treated with the 
indicated concentrations of BTD or Control conditions. Immunoreactive NKCC1 is shown in 
green. The cell nuclei were counterstaind using DAPI (experiments performed by Richa 
Singh).
BTD 10 µM BTD 100 µMControl
F
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concentration	  correlates	  with	  decreased	  NKCC1	  protein	  expression.	  Notably,	  
the	   NKCC1	   expression	   response	   to	   BTD	   in	   COS7	   cells	   follows	   a	   pattern	  
resembling	   that	   of	   MIN6	   ß-­‐cells	   (Fig	   13A).	   Further,	   to	   add	   support	   to	   the	  
notion	   that	   NKCC1	   down-­‐regulation	   may	   result	   in	   increased	   NKCC2	  
expression	  levels,	  we	  determine	  NKCC2	  protein	  expression	  in	  COS7shNKCC1,	  a	  
genetically	   engineered	   cell	   line	   stably	   expressing	   minimum	   if	   any	  
endogenous	   NKCC1	   through	   stable	   expression	   of	   shRNAs	   against	   the	  
transporter's	  RNA	  (Singh	  et	  al.	  2014)	  or	  in	  COS7shNKCC2	  recently	  developed	  in	  
our	   laboratory.	   As	   shown	   in	   Figures	   13D-­‐E,	   elimination	   of	   endogenous	  
NKCC1	  expression	  in	  COS7shNKCC1	  cells	  results	  in	  increased	  NKCC2	  expression	  
levels	   whereas	   elimination	   of	   endogenous	   NKCC2	   does	   not	   impact	   NKCC1	  
expression	   in	   COS7shNKCC2	   cells.	   Taken	   together,	   these	   results	   demonstrate	  
that	   NKCC2	   expression	   responds	   to	   decreased	   NKCC1	   levels,	   but	   not	   the	  
other	  way	  around.	  
To	   visualize	   the	   ability	   of	   BTD	   to	   deplete	   endogenous	   NKCC1	  
expression,	   COS7	   cells,	   which	   are	   big,	   flat	   and	   exhibit	   negligible	   auto-­‐
fluorescence	  (Singh	  et	  al.	  2014)	  were	  treated	  for	  16	  hours	  with	  BTD	  (10-­‐100	  
µM)	   and	   immunoreactive	  NKCC1	   assessed	  by	  using	   the	  primary	   antibodies	  
indicated	   in	   Table	   1.	   As	   shown	   in	   Figure	   13F,	   endogenous	   NKCC1	  
expression	   not	   only	   decreases	   with	   increasing	   concentrations	   of	   BTD,	   but	  
also	   redistributes	   toward	   intracellular	   compartments,	   a	   phenomenon	   that	  
correlates	  with	  visible	  cell	  shrinkage.	  	  
Long-­‐term	  BTD	  increases	  the	  rate	  of	  Cl–	  uptake	  	  
Since	   pharmacological	   or	   molecular	   depletion	   of	   NKCC1	   correlates	  
with	   increased	   NKCC2	   expression	   in	   MIN6	   ß-­‐cells	   (Figs	   13A-­‐B)	   and	   COS7	  
(Figs	  13C-­‐E),	  we	  determined	  the	  initial	  rate	  at	  which	  MIN6	  ß-­‐cells	  upload	  Cl–	  
ions	   after	   16	   hours	   of	   BTD	   treatment.	   As	   shown	   in	   Figure	   14,	   increasing	  
concentrations	   of	   BTD	   within	   the	   range	   observed	   to	   progressively	   inhibit	  
NKCC1	   expression	   and	   increase	   NKCC2	   levels	   (see	  Fig	   13)	   result	   in	   higher	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Figure 14. Long-term effect of BTD on the initial rate of Cl uptake in 
MIN6 ß-cells. MIN6 ß-cells were depleted of Cl- in Cl-free medium for
an hour (black dots) and then incubated five minutes in ISO media 
containing vehicle (red dots) or the indicated concentrations of BTD 
(colored dots). Results are expressed as nmol/µg protein/min. Each 
dot represents a single independent determination  (* p<0.05).
*
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initial	  rates	  of	  Cl–	  accumulation	  (i.e.,	  nmol	  of	  Cl–	  loaded	  per	  µg	  of	  protein	  per	  
unit	  of	   time	  computed	  during	   the	   first	  5	  minutes	  of	   the	   linear	  phase	  of	   the	  
reaction)	   relative	   to	   vehicle-­‐treated	   cells.	   These	   results	   indicate	   that	  
additional	  transport	  mechanisms	  are	  activated	  by	  long-­‐term	  treatment	  with	  
BTD.	  We	  have	  hypothesized	  that	  this	  mechanism	  is	  NKCC2.	  	  
Elimination	  of	  NKCC1	  decreases	  steady-­‐state	  total	  Cl–	  content	  
The	   following	   observations	   and	   reasoning	   are	   key	   to	   interpret	   the	  
long-­‐term	   impact	   of	   BTD	   on	   NKCC	   expression:	   i)	   long-­‐term	   treatment	   of	  
MIN6	  ß-­‐cells	  or	  COS7	  cells	  with	  BTD	  decreases	  expression	  of	  NKCC1	  (Fig	  13),	  
ii)	   NKCC1	   is	   a	   cotransporter	   directly	   involved	   in	   water	   uptake	   and	   cell	  
volume	   regulation	   (Hamann	   et	   al.	   2010),	   iii)	   ß-­‐cells	   lacking	   NKCC1	   are	  
shrunken	  (Alshahrani	  and	  Di	  Fulvio	  2012),	  iv)	  BTD-­‐induced	  down-­‐regulation	  
of	   NKCC1	   increases	   the	   levels	   of	   NKCC2	   (Fig	   13),	   and	   v)	   NKCC2	   is	   a	   "dry"	  
cotransporter	  (Zeuthen	  and	  Macaulay	  2012).	  It	  follows	  that	  NKCC2	  may	  not	  
restore	   total	   Cl–	   content	   in	   cells	   chronically	   depleted	   of	   NKCC1	   in	   spite	   of	  
increased	   initial	   rates	   of	   Cl–	   uptake	   (Fig	   14).	   To	   test	   this	   hypothesis,	   Cl–	  
uptake	  experiments	  were	  performed	  in	  COS7	  WT	  or	  COS7shNKCC1.	  As	  shown	  in	  
Figure	  15A,	  elimination	  of	  NKCC1	  in	  COS7	  cells	  results	  in	  decreased	  total	  Cl–	  
content	  incorporated	  in	  30	  minutes	  per	  µg	  of	  protein	  when	  compared	  to	  WT	  
cells	   (filled	   and	   emptied	   red	   dots,	   respectively,	   in	   Fig	   15A)	   indicating	   that	  
NKCC1	  is	  a	  major	  player	  in	  Cl–	  uptake.	  To	  determine	  the	  relative	  contribution	  
of	  NKCC2	   to	   the	   total	   pool	   of	  Cl–	   uploaded	  by	  COS7shNKCC1,	   these	   cells	  were	  
treated	   with	   10	   µM	   BTD	   during	   the	   length	   of	   the	   uptake	   experiments.	   As	  
shown	   in	  Figure	   15A,	   BTD	   decreases	   even	   further	   the	   total	   Cl–	   content	   of	  
COS7shNKCC1	   confirming	   that	   NKCC2	   is	   operative	   in	   the	   absence	   of	   NKCC1.	  
However,	   since	   NKCC2	   function	   cannot	   replace	   that	   of	   NKCC1	   in	   terms	   of	  
water	   transport	   and	   therefore	   cell	   volume	   regulation	   (Hamann	  et	   al.	   2010;	  
Zeuthen	  and	  Macaulay	  2012),	  it	  follows	  that	  [Cl–]i	  may	  be	  restored	  to	  normal	  
values	  by	  NKCC2	  function	  when	  NKCC1	  is	  absent,	  but	  not	  the	  total	  content	  of	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Figure 15. Kinetics of Cl uptake in COS7 cells. A. Cl- uptake into COS7 cells
WT (red dots) or depleted of endogenous NKCC1 (shNKCC1, blue squares), 
treated with vehicle (filled dots or squares) or 10 µM BTD (empty dots or 
squares) during the uptake reaction. Cl- uptake reaches equilibrium after ~5
minutes at room temperature and a final physiological Cl- concentration of ~140
mM. Results are expressed as mean ± SEM [n= 66 and 34 (WT and shNKCC1, 
respectively)]. The initial uptake rate is approximately linear during the first 5-10 
minutes of the reaction. Thereafter, a mono-exponential decay in the uptake 
rate can be observed. B. Kinetic parameters calculated from one-phase dacay 
best fitting analysis.

























COS7 rate k (min<1) half-life T1/2 (min) Plateau (nmol/µg protein)
WT 0.25 ± 0.06 2.73 3.3  ± 0.2
WT + BTD 0.234 ± 0.07 2.98 2.0  ± 0.1
shNKCC1 0.378 ± 0.40 1.84 2.0  ± 0.2
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the	  anion.	  
Long-­‐term	  BTD	  treatment	  does	  not	  impact	  insulin	  secretion	  in	  vitro	  
When	  applied	  acutely	  during	  minutes	  to	  islets	  or	  ß-­‐cell	  lines	  in	  vitro	  or	  
to	  mice,	  BTD	  transiently	  inhibits	  insulin	  release	  (Sandstrom	  1990)	  or	  impairs	  
glucose	   tolerance	   (Sandstrom	   1988),	   even	   in	   mice	   lacking	   NKCC1	  
(Alshahrani	  and	  Di	  Fulvio	  2012).	  Further,	  if	  NKCC2	  function	  restores	  [Cl–]i	  in	  
ß-­‐cells	  lacking	  NKCC1,	  then	  long-­‐term	  treatment	  of	  these	  cells	  with	  BTD	  may	  
not	  negatively	   impact	   insulin	   secretion.	  To	   test	   the	   long-­‐term	  effect	  of	  BTD	  
on	  insulin	  secretion	  in	  vitro,	  we	  first	  confirmed	  the	  ability	  of	  MIN6	  ß-­‐cells	  to	  
secrete	   insulin	   after	   challenging	   them	  with	   physiological	   concentrations	   of	  
glucose,	  as	  shown	  in	  Figure	  16A.	  Then,	  we	  either	  pre-­‐incubated	  MIN6	  ß-­‐cells	  
with	   10	   µM	   BTD	   for	   16	   hours	   or	   incubated	   them	   for	   the	   length	   of	   time	  
required	  to	  assay	  insulin	  secretion	  in	  response	  to	  glucose	  in	  vitro	  i.e.,	  2	  hours.	  
As	   shown	   in	   Figure	   16B,	   end-­‐point	   basal	   or	   glucose-­‐stimulated	   insulin	  
secretion	   in	   the	   presence	   of	   BTD	   was	   not	   different	   from	   that	   of	   Control.	  
These	  results	  suggest	  that	  long-­‐term	  action	  of	  BTD	  does	  not	  impact	  the	  total	  
amount	   of	   insulin	   secreted	   by	   MIN6	   ß-­‐cells	   during	   the	   assayed	   period	   of	  
time.	  






























































Figure 16. Glucose-induced insulin secretion. A. MIN6 ß-cells 
were incubated with the indicated concentrations of glucose (GLU) for 
2 hours. Then, insulin secreted into the media and total cellular insulin 
content were measured using ELISA Results are expressed as % 
increase of insulin secreted into the media over basal levels i.e., those 
obtained at GLU <5.5 mM (n=13). B. Short and long term  BTD  (10 
µM) effects on insulin secretion from MIN6 cells: Insulin secretion and 
content from MIN6 control (red), treated with BTD 2h (green) or 16 h 
(blue) incubated with low (5.5 mM) and high (20 mM) glucose 
concentration were meaured using ELISA. Insulin secretion was 
related to total insulin content (insulin secretion/total insulin content) 




























Previous	  experiments	  have	  demonstrated	  that	  NKCC1	  and	  NKCC2	  are	  
co-­‐expressed	  in	  the	  rodent	  islet,	  precisely	  in	  insulin-­‐secreting	  ß-­‐cells	  but	  not	  
in	  other	  endocrine	  cells	  of	  the	  islet	  (Alshahrani	  et	  al.	  2012;	  Alshahrani	  and	  Di	  
Fulvio	   2012).	   These	   results	   coupled	   to	   the	   fact	   that	   NKCC1a	   and	   NKCC2A	  
were	  the	  splice	  variants	  detected	  at	  the	  molecular	  levels	  in	  two	  different	  rat	  
ß-­‐cell	   lines	   i.e.,	   INS-­‐1E	  and	  RIN-­‐m5F	  (Alshahrani	  et	  al.	  2012),	  gave	  origin	  to	  
the	  suggestion	  that	  rodent	  islets	  express	  these	  NKCC	  variants	  and	  not	  others.	  
However,	   our	   results	   indicate	   that	   NKCC1a,	   NKCC1b	   and	   NKCC2F	   are	   co-­‐
expressed	   in	   the	   mouse	   ß-­‐cell	   line	   MIN6	   and	   islets	   (Fig	   10B	   and	   11A,	  
respectively).	  The	  finding	  of	  very	   low	  transcript	   levels	  of	  NKCC1b	  in	  mouse	  
but	   not	   in	   rat	   ß-­‐cells	   cell	   lines	   suggests	   either	   i)	   species	   differences,	   or	   ii)	  
higher	  expression	   levels	  of	  NKCC1	  mRNAs	   in	   the	  mouse	   islet	  or	  ß-­‐cell	   lines	  
relative	  to	  the	  rat	  counterpart.	  Examples	  of	  the	  former	  argument	  abound	  in	  
the	   literature.	   It	   is	   estimated	   that	   >11%	   of	   conserved	   exon	   cassettes	   are	  
spliced	   out	   in	   human	   but	   constitutively	   included	   in	   mouse	   transcripts	  
(Barbosa-­‐Morais,	   et	  al.	  2012;	  Pan,	  et	  al.	  2005).	  Relative	   to	  ß-­‐cells,	   the	  most	  
prominent	   example	   of	   species-­‐specific	   gene	   expression	   is	   the	   vesicular	  
monoamine	   transporter	   2	   (VMAT2),	   which	   is	   abundantly	   expressed	   in	  
porcine	   and	   human	   ß-­‐cells	   but	   undetectable	   in	   rat	   or	   mouse	   laboratory	  
strains	  (Schafer,	  et	  al.	  2013).	  In	  addition,	  NCC	  is	  detected	  in	  MIN6	  ß-­‐cells	  (Di	  
Fulvio	  et	  al.	  2014)	  but	  not	  in	  mouse	  islets	  (results	  not	  shown).	  Moreover,	  we	  
have	  to	  keep	  in	  mind	  that	  undetectable	  levels	  of	  NKCC1b	  in	  rat	  ß-­‐cells	  or	  any	  
transcript	  in	  any	  cell	  type	  or	  tissue	  is	  always	  subjected	  to	  our	  ability	  to	  detect	  
it,	   in	   particular	   when	   expressed	   at	   low	   levels	   and	   when	   the	   source	   of	  
transcripts	   is	   a	   pure	   cell	   line	   growing	  under	   specific	   conditions	   or	  purified	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from	   tissues,	   as	  we	  have	   recently	   observed	   in	   COS7	   cells	   and	  brain	   tissues	  
(Singh	  et	  al.	  2014).	   In	  addition,	  NKCC1b	  appears	  to	  contribute	  minimally	  to	  
the	   total	   pool	   of	   NKCC1	   transcripts	   in	   ß-­‐cells,	   although	   its	   relative	   mRNA	  
expression	  varies	  widely	   in	  different	   tissues	   (Vibat	  et	  al.	  2001).	   Indeed,	  we	  
estimated	   that	   NKCC1b	   corresponds	   roughly	   to	   ~1%	   of	   the	   total	   NKCC1	  
transcripts	  in	  MIN6	  ß-­‐cells,	  explaining	  the	  undetectable	  levels	  of	  NKCC1b	  in	  
previous	   reports	   (Alshahrani	   et	   al.	   2012).	  Although	   additional	   experiments	  
are	   required	   to	   determine	   potential	   inter-­‐species	   differences	   in	   the	  
expression	   pattern	   of	   Slc12a	   genes	   in	   ß-­‐cells,	   the	   fact	   that	   some	   genes	   are	  
clearly	  detected	  in	  cell	  lines	  relative	  to	  primary	  cells	  or	  tissues	  suggests	  that	  
caution	  should	  be	  paid	  before	  extending	  results	   from	  cell	   lines	  to	  tissues	  or	  
from	  one	  species	  to	  another.	  
	  
Relative	   to	  NKCC2	  expression	   in	   rodent	  ß-­‐cells	   and	   islets,	  molecular	  
cloning	   and	   sequence	   analysis	   demonstrated	   that	   NKCC2A	   is	   expressed	   in	  
INS-­‐1E	   and	   RIN-­‐m5F	   rat	   ß-­‐cells	   lines.	   However,	   the	   molecular	   identity	   of	  
NKCC2	   expressed	   in	   rat	   or	   mouse	   islets,	   was	   not	   determined	   at	   that	   time	  
(Alshahrani	  et	  al.	  2012).	  The	   finding	  that	  NKCC2F	  is	  expressed	   in	  mouse	  ß-­‐
cells	  and	  mice	  islets,	  including	  those	  of	  the	  NKCC2A-­‐KO	  genotype,	  but	  not	  in	  
rat	   ß-­‐cell	   lines	  minimizes	   the	   possibility	   that	  NKCC2F	   is	   the	   compensatory	  
result	  of	  NKCC2A	  absence	  in	  the	  islet.	  However,	  this	  possibility	  may	  remain	  
open	  due	  to	  the	  fact	  that	  MIN6	  ß-­‐cells	  are	  derived	  from	  in	  vivo	  immortalized	  
ß-­‐cells,	   which	   may	   not	   represent	   the	   normal	   population	   of	   ß-­‐cells.	   In	  
addition,	  mice	  ß-­‐cells	  may	  express	  NKCC2A	  mRNAs	  at	   levels	   low	  enough	  to	  
be	  under-­‐represented	  by	  our	  RT-­‐PCR	  assays.	  Indeed,	  nested-­‐PCR	  of	  NKCC2-­‐
700	   amplicon	   obtained	   from	   WT	   islets	   was	   necessary	   to	   yield	   sufficient	  
product	   for	   DNA	   sequencing	   and	   the	   nucleotide	   sequence	   chromatogram	  
corresponded	   to	  exon	  F	  of	  NKCC2	   (see	   Figs	  10C-­‐D	  and	  11B-­‐C).	  Because,	  no	  
other	  DNA	  sequences	  were	  detected,	  we	  concluded	  that	  NKCC2A	  or	  NKCC2B	  
are	  either	  expressed	  at	  levels	  bellow	  the	  detection	  limit	  or	  not	  expressed	  at	  
all.	   Irrespective	   of	   the	   splice	   variants	   of	  NKCC2	  or	  NKCC1	   expressed	   in	   rat	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and	   mouse	   ß-­‐cells,	   our	   results	   clearly	   showed	   that	   both	   transporters	   co-­‐
localize	   in	   insulin-­‐positive	   cells	   of	   the	   islet	   (Figs	   11D-­‐E).	   These	   results	   not	  
only	   confirm	   and	   extend	   previous	   findings	   (Alshahrani	   et	   al.	   2012;	  
Alshahrani	   and	   Di	   Fulvio	   2012),	   but	   also	   support	   the	   notion	   that	   both	  
cotransport	   systems	   may	   participate	   in	   the	   regulation	   of	   [Cl–]i	   in	   ß-­‐cells,	  
regardless	  of	  the	  rodent	  species.	  
	  
Indeed,	  our	  experiments	  demonstrated	  that	  MIN6	  ß-­‐cells	  depleted	  of	  
endogenous	   Cl–	   accumulate	   the	   anion	   as	   a	   function	   of	   time	   in	   a	   way	  
resembling	   first-­‐order	  kinetics	   (Fig	  12A)	  with	  a	  constant	   rate	  of	  0.124/min	  
and	   a	   half-­‐life	   of	   5.6	   min.	   However,	   short-­‐term	   BTD	   treatment	   at	  
concentrations	   known	   to	   inhibit	  NKCC	   function	   (Gamba	  2005)	   significantly	  
reduced	   total	   Cl–	   accumulation	   in	   these	   cells	   (Fig	   12A)	   but	   it	   did	   not	  
completely	   block	   it,	   indicating	   that	  ß-­‐cells	   uptake	  Cl–	   ions	  by	  using	   at	   least	  
two	  different	  mechanisms:	  one	  of	  them,	  which	  accounts	  for	  ~40%	  of	  total	  Cl–	  
uptake	   (Fig	   12A),	   is	   BTD-­‐dependent	   and	   has	   an	   estimated	   IC50	   for	   the	  
diuretic	  of	  ~8	  µM	  (Fig	  12B).	   In	  analogy,	  approximately	  40%	  of	   the	   total	  Cl–	  
accumulated	   in	  mice	   islets	  was	   sensitive	   to	   10	   µM	  BTD	   as	  well	   	   (Fig	   12C).	  
Since	  BTD	  inhibits	  NKCC1	  and	  NKCC2	  with	  an	  IC50	  reported	  within	  the	  range	  
of	  0.5-­‐20	  µM	   (Gamba	  2005;	  Haas	  and	  McManus	  1983;	  Homma,	   et	   al.	   1990;	  
Markadieu	   and	   Delpire	   2014;	   Plata,	   et	   al.	   2002;	   Russell	   2000;	   Vigne,	   et	   al.	  
1994)	  and	  both,	  NKCC1	  and	  NKCC2	  are	  expressed	  in	  MIN6	  ß-­‐cells	  and	  mice	  
islets,	   our	   results	   support	   the	   notion	   that	   these	   cells	   express	   functional	  
NKCCs	   and	   that	   they	   accumulate	   Cl–	   actively	   to	   concentrations	   above	  
thermodynamic	   equilibrium.	   This	   concept	   is	   in	   agreement	   with	   [Cl–]i	  
calculated	   and	   directly	   measured	   in	   other	   rodent	   ß-­‐cells	   and	   islets	  
(Eberhardson	   et	   al.	   2000;	   Kozak	   and	   Logothetis	   1997).	   However,	   our	   Cl–	  
uptake	   experiments	   performed	   in	  MIN6	  ß-­‐cells	   or	   islets	   do	   not	   distinguish	  
whether	  NKCC1,	  NKCC2	  or	   both	   transport	   systems	   are	   actively	   involved	   in	  
that	  process.	  The	  very	  low	  levels	  of	  NKCC2	  detected	  in	  ß-­‐cells	  or	  islets	  (Figs	  
10C,	   11B	   and	   13A)	   (Alshahrani	   et	   al.	   2012)	   relative	   to	   NKCC1	   may	   argue	  
           63
against	   the	   idea	   that	  NKCC2	  participates	   in	   [Cl–]i	   physiology,	   at	   least	  under	  
normal	  conditions.	  Our	  novel	   findings	   that	  COS7shNKCC1	   cells	   lacking	  NKCC1,	  
but	   expressing	  NKCC2	   (Figs	  13D-­‐E)	   accumulated	  Cl–	   ions	   in	   a	   lesser	   extent	  
relative	  to	  WT	  cells	  and	  that	  this	  accumulation	  decreased	  even	  further	  after	  
BTD	   treatment	   (se	   Fig	   15A)	   strongly	   suggest	   that	  NKCC2	   is	   active,	   at	   least	  
when	   NKCC1	   is	   absent.	   Clearly,	   these	   experiments	   cannot	   answer	   the	  
question	  as	  to	  what	  is	  the	  relative	  proportion	  of	  each	  cotransporter	  involved	  
in	   Cl–	   uptake	   when	   both	   are	   co-­‐expressed.	   Based	   on	   the	   very	   high	  
NKCC1/NKCC2	  expression	  ratio,	  it	  is	  tempting	  to	  speculate	  that	  NKCC1	  plays	  
a	  major	  role	  in	  Cl–	  uptake	  in	  MIN6	  and	  COS7	  cells	  and	  that	  NKCC2	  may	  have	  a	  
secondary,	  less	  important,	  if	  any	  role	  under	  normal	  conditions.	  
	  
The	   previous	   conclusion	   begs	   the	   question:	  What	   is	   the	   function	   of	  
NKCC2	  in	  ß-­‐cells?	  Our	  results	  demonstrate	  that	  long-­‐term	  treatment	  of	  MIN6	  
ß-­‐cells	   or	   COS7	   cells	   with	   BTD	   results	   in	   decreased	   endogenous	   NKCC1	  
expression	  (Figs	  13A-­‐C).	  To	  the	  best	  of	  our	  knowledge,	  this	  surprising	  effect	  
of	  BTD	  was	  not	  observed	  before,	  probably	  due	  to	  the	  fact	  that	  the	  effects	  of	  
BTD	  on	  NKCCs	  have	  been	  studied	  in	  short-­‐term	  experiments	  looking	  almost	  
exclusively	   at	   the	   functional	   properties	   of	   the	   transporter	   (Gamba	   2005;	  
Russell	   2000).	   Notably,	   BTD-­‐induced	   NKCC1	   down-­‐regulation	   was	   dose-­‐
dependent	   and	   reached	   a	   maximum	   inhibitory	   effect	   at	   concentrations	  
around	  5	  µM	  (Figs	  13A-­‐B),	  a	  value	  very	  close	  to	  that	  required	  to	  inhibit	  half	  
of	  functional	  endogenous	  NKCC1	  in	  many	  cell	  systems	  (Gamba	  2005;	  Russell	  
2000)	   and	   NKCC-­‐mediated	   Cl–	   uptake	   in	   rodent	   ß-­‐cells	   (Sandstrom	   1990;	  
Sandstrom	  and	  Sehlin	  1987),	  including	  MIN6	  (Fig	  12B).	  These	  results	  suggest	  
that	   functional	   inhibition	  of	  NKCC	  with	  BTD	  and	  the	  observed	  BTD-­‐induced	  
down-­‐regulation	   of	   NKCC1	   expression	   may	   be	   related.	   Interestingly,	   the	  
latter	  phenomenon	  was	  observed	  in	  MIN6	  and	  COS7	  cells	  (see	  Fig13),	  further	  
suggesting	   that	   the	   inhibitory	   effect	   of	   BTD	   on	   NKCC1	   expression	   is	  
independent	   of	   the	   cell	   type	   and	   that	   similar	  mechanisms	   are	   operative	   in	  
both	   cell	   types.	   Although	   the	   mechanisms	   whereby	   BTD	   decreases	   NKCC1	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expression	   in	   these	   cells	   remain	   unknown,	   NKCC1	   immuno-­‐localization	  
analysis	   of	   COS7	   cells	   treated	   long-­‐term	  with	   BTD	   revealed	   an	   interesting	  
feature:	   vacuolization	   of	   endogenous	   immunoreactive	   NKCC1	   (Fig	   13F)	  
which	  resulted	   in	  apparent	  retention	  of	   the	  transporter	   in	   the	  cytoplasm	  of	  
the	   cells	   and	   down-­‐regulation.	   This	   result	   resembles	   that	   of	   receptor-­‐
mediated	   endocytosis,	   whereby	   ligands	   e.g.,	   BTD	   may	   be	   internalized	   and	  
their	   receptors	   e.g.,	   NKCC1	   degraded	   not	   only	   ceasing	   trans-­‐membrane	  
signaling	  but	  also	  transducing	  signals	  from	  the	  cell	  surface	  to	  the	  nucleus	  in	  
the	   form	  of	   long-­‐term	   responses	   i.e.,	   gene	   expression	   (Alberts,	   et	   al.	   2008).	  
Our	  results	  demonstrate	  that	  long-­‐term	  pharmacological	  down-­‐regulation	  of	  
NKCC1	  in	  MIN6	  and	  COS7	  cells	  increases	  NKCC2	  expression	  (Figs	  13A-­‐C)	  and	  
that	   this	   phenomenon	   appears	   related	   to	   a	   chronic	   down-­‐regulation	   of	  
NKCC1	   expression	   rather	   than	   an	   independent	   increase	   in	   NKCC2	   in	  
response	   to	   BTD	   in	   vitro.	   Indeed,	   molecular	   elimination	   of	   endogenous	  
NKCC2	   did	   not	   result	   in	   increased	   NKCC1	   expression	   (Fig	   13E)	   thus	  
suggesting	  that	  up-­‐regulation	  of	  NKCC2	  in	  MIN6	  or	  COS7	  cells	  treated	  long-­‐
term	   with	   BTD	   occurs	   in	   response	   to	   NKCC1	   depletion	   and	   that	   NKCC1	  
expression	  is	  refractory	  to	  absent	  NKCC2.	  
	  
The	   most	   parsimonious	   functional	   consequence	   of	   long-­‐term	   BTD	  
treatment	   is	  a	  chronic	  drop	   in	   [Cl–]i,	   cell	  volume	  or	  both,	  providing	  no	   fully	  
compensatory	   mechanisms	   are	   triggered	   in	   a	   given	   cell	   and	   the	   effects	   of	  
BTD	   are	   specific	   of	   NKCCs.	   Clearly,	   NKCC2	   cannot	   compensate	   for	   NKCC1	  
function	   as	   the	   former	   is	   incapable	   of	   moving	   water	   across	   plasma	  
membranes	   (Zeuthen	  and	  Macaulay	  2012)	  whereas	   the	   latter	  upload	  ~500	  
molecules	   of	   water	   per	   ion	   transport	   cycle	   (Hamann	   et	   al.	   2010).	   These	  
concepts	   are	   consistent	   with	   the	   finding	   that:	   i)	   ß-­‐cells	   lacking	   NKCC1	  
COS7shNKCC1	   are	   shrunken	   [(Alshahrani	   and	   Di	   Fulvio	   2012)	   and	   data	   not	  
shown]	   and	   ii)	   MIN6	   ß-­‐cells	   or	   COS7	   cells	   treated	   long-­‐term	   with	   BTD	  
accumulate	  Cl–	  at	  higher	  initial	  rates	  relative	  to	  non-­‐treated	  cells	  (Figs	  14	  and	  
15,	   respectively)	   whereas	   total	   Cl–	   accumulation	   in	   COS7shNKCC1	   cells	   is	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decreased	  relative	  to	  WT	  (Fig	  15A).	  Therefore,	   these	  results	  are	  compatible	  
with	   the	   suggestion	   that	   up-­‐regulation	   of	   NKCC2	   in	   response	   to	  
pharmacological	  inhibition	  of	  molecular	  depletion	  of	  NKCC1	  may	  restore	  [Cl–
]i,	  but	  not	  cell	  volume.	  However,	  we	  have	  to	  keep	  in	  mind	  that	  BTD	  may	  have	  
off-­‐target	  effects	  that	  might	  potentially	  impact	  the	  overall	  physiology	  of	  [Cl–]i.	  
For	   instance,	   the	   BioActivity	   data	   for	   BTD	   posted	   in	   PubChem	   database	  
indicates	   that	   this	   diuretic	   at	   half-­‐maximal	   concentrations	   of	   6-­‐25	   µM	   is	  
active	   in	   28	   out	   of	   1209	   bioassays	   performed	  
(pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?cid=2471).	   These	   include	  
inhibition	  of	  the	  nuclear	  factor	  erythroid	  2-­‐related	  factor	  2	  isoform	  2	  (NRF2),	  
a	   basic	   leucine	   zipper	   transcription	   factor	   that	   maintains	   cellular	   redox	  
homeostasis	   protecting	   cells	   from	   toxic	   xenobiotics	   (Ma	   2013),	   17-­‐ß-­‐
hydroxysteroid	   dehydrogenase-­‐4,	   an	   enzyme	   involved	   in	   the	   conversion	   of	  
estrogens	  and	  androgens	  from	  17-­‐hydroxisteroids	  (de	  Launoit	  and	  Adamski	  
1999),	   carbonic	   anhydrases	   (CA5B,	   CA13	   and	   CA14)	   involved	   in	   the	  
bidirectional	  inter-­‐conversion	  between	  bicarbonate	  and	  protons	  from	  carbon	  
dioxide	   and	   water	   (Lindskog	   1997),	   or	   MEK5,	   a	   dual	   specificity	   protein	  
kinase	  of	  the	  STE7	  family	  of	  kinases	  (Kato,	  et	  al.	  2000).	  Additional	  complexity	  
to	   the	   interpretation	  of	   functional	   data	   obtained	  by	  using	  BTD	   comes	   from	  
the	  facts	  that	  BTD	  is	  also	  a	  direct	  inhibitor	  of	  the	  cystic-­‐fibrosis	  conductance	  
regulator	   (CFTR),	   an	   anion/Cl	   channel	   (Ju,	   et	   al.	   2014)	   and	   the	   human	   G-­‐
protein	  coupled	  receptor-­‐35	  (GPR35)	  (Yang,	  et	  al.	  2012).	  	  	  
	  
Since	  acute	  insulin	  secretion	  depends	  on	  [Cl–]i	  above	  thermodynamic	  
equilibrium	  (Best	  2005)	  and	  the	  depolarizing	  efflux	  of	  Cl–	  via	  VRAC	  requires	  
glycolysis-­‐induced	  ß-­‐cell	   swelling	   (Best	   et	   al.	   2010),	   it	   follows	   that	   the	   up-­‐
regulation	   of	   NKCC2	   in	   MIN6	   ß-­‐cells	   observed	   in	   response	   to	   long-­‐term	  
down-­‐regulation	   of	   NKCC1	   (Figs	   13A-­‐B)	   may	   protect	   the	   insulin-­‐secretory	  
capacity	  of	  the	  ß-­‐cell	  to	  the	  action	  of	  BTD.	  This	  hypothesis	  is	  consistent	  with	  
our	  results	  showing	  that	   long-­‐term	  treatment	  of	  MIN6	  ß-­‐cells	  with	  BTD	  did	  
not	  result	  in	  impaired	  insulin	  secretion	  in	  response	  to	  glucose	  (Fig	  16B).	  This	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result	   cannot	   be	   seen	   as	   challenging	   those	   previously	   published	   studies	  
wherein	  BTD	  or	  furosemide	  inhibited	  insulin	  secretion	  in	  isolated	  rodent	  ß-­‐
cells,	  islets	  or	  glucose	  homeostasis,	  simply	  because	  the	  action	  of	  the	  diuretics	  
were	   tested	   for	   minutes	   (Sandstrom	   1988,	   1990;	   Sandstrom	   and	   Sehlin	  
1988a,	   b,	   c).	   In	   fact,	   even	   an	   hour	   of	   BTD	   treatment	   resulted	   in	   decreased	  
insulin	   concentrations	   in	   the	   media	   of	   INS-­‐1E	   ß-­‐cells	   (Alshahrani	   and	   Di	  
Fulvio	   2012).	   Notably,	   the	   amount	   of	   insulin	   released	   into	   the	   cell	   culture	  
media	   as	   a	   proportion	   of	   the	   total	   cellular	   content	   of	   the	   hormone	   did	   not	  
change	  when	  MIN6	  ß-­‐cells	  were	  co-­‐incubated	  with	  BTD	  for	  the	  time	  period	  
involved	  in	  the	  insulin	  assay	  (2	  hours,	  Fig	  16C).	  However,	  our	  results	  cannot	  
discard	  the	  possibility	  of	  impaired	  kinetics	  of	  insulin	  release	  in	  particular	  the	  
rate	   of	   insulin	   release	   during	   the	   first	  minutes	   of	   glucose	   challenge.	  When	  
these	  results	  are	  placed	  together	  with	  those	  related	  to	  the	  impact	  of	  BTD	  on	  
NKCC	  expression	  and	  Cl–	  regulation	  (Figs	  12-­‐16),	  it	  is	  reasonable	  to	  support	  
the	  hypothesis	  that	  long-­‐term	  BTD	  does	  not	  impair	  insulin	  secretion	  from	  ß-­‐
cells	  in	  vitro	  due	  to	  up-­‐regulation	  of	  NKCC2,	  a	  transporter	  expressed	  in	  these	  
cells	  at	  very	  low	  levels	  under	  normal	  conditions.	  However,	  these	  results	  must	  
be	  taken	  with	  caution	  because	  NKCC2	  is	  also	  a	  target	  of	  BTD	   in	  vitro	  and	   in	  
vivo	  (Gamba	  2005)	  although	  at	  concentrations	  higher	  than	  those	  required	  to	  




Taken	   together,	   the	   results	  presented	   in	   this	  Thesis	   suggest	   that	   the	  
functional	  long-­‐term	  balance	  between	  NKCC1	  and	  NKCC2	  co-­‐expressed	  in	  ß-­‐
cells	   keeps	   insulin	   secretion	   within	   normal	   ranges	   and	   that	   long-­‐term	  
pharmacological	   inhibition	   or	   molecular	   depletion	   of	   NKCC1	   activates	  
mechanisms	  aimed	  at	  restoring	  [Cl–]i	   in	  ß-­‐cells	  and	  therefore	  it	  may	  protect	  
ß-­‐cells	  against	  inhibition	  of	  insulin	  secretion.	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